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NTPOau1 NTPDan2 NTPDase3 
COOl ' 
NTP-O .... et4 
(UDPaso) 
NT PO;oIIIi(tS 
I:CD!9LA) 
N" POa.tI06 
(CD3~L2.1 
NlP ,.,.,p. 2 Pi NTP' HOP • Pi NTP · NOl'I r i UDI" U,.. I Pi 
NOP - Mj,P .. P1 IHOP ~ HI.IP + Pli NOf> _ HiliI' .. Pt UrI' _ ue." .. PI NrJP - fNP , PI HOP - NMP .. PI 
IA li' :AOSl ." l:U-lI~ I" TP:ACW = 1 :O.t(3) (ATP:40P" ' ''il .;J,I 
l"igtlre 2.2.1 - The E-~TPDase famll~' of t>eto-rHltleoddases. 
A diagrammatit repr~s{'ntatioh of the E-l\TPOase ('atlJiI~' showing 
NTPlhtsesl-fl. Th('Jr alt('rnate lHunes ~trt' shown in parentheses belo~' . 
Apyrase consened regions are demonstrat('d as bJaek boxes in the 
extracl'lIuJar domain. The enz~'mati{" adions and ATPase:ADPase ratios 
of eath eetonudeotidase an' shoun be I 0\'''' the diagrams. Note that 
NTPOasesl-3 are ('xpressed in the plasma membrane with their 
em) mafic domains fa<"ing the extraceliuJar space. In {"ontrast, NTPOases 
4-6 reside in either the Goigi or ('ndoplasmk reticulum. 
(Image: f'igure 1 in Zimmermann, H. Extra~lIular metabolism of Al'P 
and other nucleotidt.>s . .:Varlllyn-Schmiedeberg\ An:h f'lurrmacol 12(00) 
362:299-309. :f.'lgure reprinted with permission). 
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Figure 2.2.2 - Graphical epresentation of the action of CD39 on 
extracellular nucieotides, ATP and ADP. 
ATP and ADP are released at the site of tissue damage, where they 
induce platelet activation. CD39 (represented by the gold rings on the 
endothelial surface and on the surface of monocytes (Mo)) hydrolyzes 
A TP and ADP to AMP, thus limiting platelet aggregation. AMP is 
further hydrolysed by 5'-nucleotidase (5'NT) to adenosine, which has 
anti-inflammatory and anti-aggregatory effects. (Image courtesy of Dr. 
Simon Robson). 
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figure 4 .. 1.1 . Generation f}f the Cd39·null mouse 
a,l Rf'Strjction l'nzyme sUe map of mouse Cd39 ~eue, BflmJlI rt"S{rict'lons sites art denoted by 
thin \'c-rtical LInes: exonsiffiolm b} 1hick \ertical lines, >2!'kbs;ectlolli represents Q large 
inlron hetween exons I and II, 
b) Targeti.n~ of IIlI? CdJ9 !!ene. D.\ (Thick horizontal bllT J. probe used fur Soutbern blot 
anal~'sis: Hatched borizonml bars. fragnu'n(s ~enerattd ~ith ttHo UJ probe (sizes sho\\u 
on the righu: peR primers (smiilll arrowheads) used for tbe conllrmatlon of homologous 
recombination; TK. thymidine kinase: Neo, neom}cin resistance gl'ne. 
l') Southem blot analysis with the DJ probe sho"in~ hf}lJ104ogolJS recombfnlttion at J' end. 
4.2·kb or 35·kb BKIlI fragnlenl5 generated b}' D3 h~'bridizatioll to wlld·type or targeted 
alleles., Ge'flot}'pe deuott'd blow Ihe blot. 
d) peR analysis 01' clones at lhe S' end (primers 1 and 2 used fo generate ao 1I,5·kb prooucn. 
Genot)'pe den01ed blow tbe blot. 
Image: Fi~urt." 1 in Eu,lJoJi. K. el OIL TargNed disruption or rd39/ATP djpbospho-hydTolase 
rel'>ulb 1n disorden:d bemOSlas.is and thrombore~ulatioD, ,Vitlllrl' mt'dh';t1{' 5. 1010·7 41999.1. 
Reprinted with permission. 
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Image: Figure 2 in £njyoji, K. (>t al. 
Targeted disruption 01' cd39lATP 
diphosplw.h),'<1rolase results in diS<lrdered 
hemostasis anti lhrombor~ulati{)/l. NlItuTe 
medicine 5. 1010·7 (999). Reprinted with 
permission. 
F'igun 4.1.2 
Confirm a ti()Jl of Cd39 deletion in 
the C<139-null mouse by analysis of 
mRNA and protein expres.~ion as 
well a.... functional ('ctonucieotidase 
acth'ity. 
a) 
b) 
u) 
Northern bJoI analysis C<139 
mRNA expression [rom aduJt 
mouse organs. (;enotypes 
shown hdow the blot. 
Glyceraldehyde 3'phosphate 
dehydrogenase «(;3POH:1 
controls are shown below. 
Western blot analJ"sis of 
transfeC'ted COS-7 ce Us u~dng 
a Cd39-spe-cific polyclonal 
:mtibod)'. Lane I: empty 
,-(>('tor; lane 2: Ctl39 
expression ve~tor; lanes 3·8: 
lung homogeIlates and 
membrane fr.lctions from 
wUd-t)'pe and Cd39-nuJl mice. 
Gtc'notypes shown below the 
blot. 78kOa: "ath'e prottc'in; 
56kDa: proteolytic form 
ATPase.. ADPase D, 
acthity of ,rarious murine 
organs (pmolfuin) ll)' 
phosphate rel~ase foJlowing 
addition of ATP and ADP. 
Genot)'pt.'s show n below 
graph_ 
ATPa.~e •. AOPuse D, 
activit}' of wild-t)'pe and CdJ9-
null mlll-jne enduthelial ceJl 
cultures. Genotypes shown 
below the g'raph. 
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Figure 4.1.3 - OE'crea.<;ed inhihition of platelet aggregation by Cd39-null 
endothelial cells. lO~M ADP was added to human platelets in th", presence of 
wiJd-type. Cd39-nuU. or no endutht'lial tells and pJatdet activation measur.-:d b~" 
crumges in light lran.<;mbsjon. Platelets in the pJ'eS<'ru:-e of wiJd-type kd.39+1+) 
endothf.>lial cells experif.>n('e aJmo!tt no aggregation in response to AUf'. 
Image: Figure 3 in EnJ\'oJi, K. et al. Targeted rusruptlon of td39/ATP 
diphospho-h) .. drola~ results in disordered hemostasis and thromboregulation. 
Na/ure medicine 5,10]0-7 (1999), Reprinted with permission. 
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F'igure 4.2.1 - Mouse genot)'ping 
Representative examph.' of Southern blot analysis of mouse genot~'p€. 
ONA was extrae'ted from the lails of 11 different mice. Samples 
represent peR amplification of t'xtraded n~A using primers 
recognizing wild-t)-p€ and CdJ9-nuU DNA sequences. Murine genot)pe is 
re-presen.ted by the presence of wild-t).pt. Cd.39-nuU or both ONA 
sequences. 
Mke numbered 2. 5. 6, 8 and 9 are wild-t~"pe. Mi<.'e numbered I. 3,4. 7. 
11 and 12 are Cd39 helerul.ygotes. Mouse number 10 l, Cd39-nuH. 
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Figure 4.3.1 Matrigd plug InullIlIlohistocbemistry. Wild.t}'pt' 
(eI, c) and Cd39·nuJl (/J. tI) matrigel plugs are stained wUh antibodies recognizing 
CDJI. BnckeUed areas represt'nt t\fauigel. d and l', CD31+ endo1hellal cells are 
seen imadlng: MatrigeJ plugs and forming new "essels In wild-t}'pt' mice. band d, 
CDJI+ endothelial ct'lls ,Ire unable 10 pene1rale :\tatrlgeJ in CJ3.9·null ~mirnal!>. 
Bars;:25/~rn It-, rl) and 200 Jim (3 and bt. 
Imal,:e: Figure 1 ill Goepfert C et al. Di<;.{)rdered cellular migration ilnd 
anglogene!>is io cdJ9·null mire. Orclltunon 104,3109·15 (lOOl). Reprillttd with 
permission. 
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f'igurt' 4.3.2 . Matrigel plug illlmunohistoch~nJ.is.tTl' 
IntI" mnm~:>ry 
u-b: Hematoxylin-rosin r.1'lin or tDe interfa~ between dermis a.nd Matrigel Ln wHd-tlpe fa) 
and CdJ9·nulJ (b} mit-e. Note th.t" lack of cellular infiltration 01' Matrigel in CilJ9·nuli animals. 
{'·f: F4i80·maITophage stain of Mat~el pJugs in wjld.tn>e ({', £',1 and Cd39'null (d, fJ mke. 
While ~t\"nsh'e iums.lon or Rlilcropbages ocrurs tn tbe Wild-type, " compact rim of 
m.aeropha.g{'~ develops at the dermislMatrige1 iutel;a{'{' in Cd39·null mire-. 
Bar ..... 2S Jim (fI, b, t:,fl and 200 jlll1 (t:, tl). 
Image: Figure 2 in Goepfert C et "I. Disordered c~lIular mJgration and angiogenesis in cdJ9· 
null rnlee, Cir('ufuriml 104,3109-15 (2001). Rt'prlnlffi with permission. 
120 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
121 
4.3.3 Dis(~ussion 
MatrigeFM plug angiogenesis assays have provided a useful methodology 
for studying angiogenesis in vivo. Despite the addition of proangiogen IC 
factors VEGF, FGF and sphingosine-I-phosphate into the rv1atrigeF"'1, there 
was complete failure of angiogenesis in the Cd39-null mice. Several of the 
initial phases of angiogenesis, including vascular activation and loosening of 
peri-endothelial pericyte support, occurred in Cd39-rmU animals. However, 
there were significant defects in migration of all cellular lines into the 
Matrigel™ and a complete failure to form new vasculature vvithin the 
MatrigejTM .214 These results suggest that physiological and pathological 
angiogenesis may be affected by the deletion of Cd39 and prompted further 
study of angiogenesis during liver regeneration, myocardial infarction and 
tumour growth and metastasis in Cd39-null mice. 
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4.4 LIVER REGENERATION 
4.4.1 Introduction 
Liver regeneration is a vitaHy important physiological process, which occurs 
aCter liver resection, Jiver transplantation and after toxic or viral hepatic 
injury.22o In addition to hepatocyte proliferation, the formation of new 
hepatic sinusoids by angiogenesis is considered crucial for effective liver 
regeneration. xl This has been demonstrated, at least in an animal model, by 
showing that the angiogenesis inhibitor angiostatin can inhibit liver 
regeneration in vivo, despite having no direct actions on hepatocytes. 221 
Initially, after significant liver resection, hepatocytes are induced to 
proliferate with peak DNA synthesis occuning at 24 hours (figure 4.4.1). 
This creates avascular parenchymal islands of hepatocytes without normal 
sinusoidal architecture (figure 4.4.2). In response, sinusoidal endothelial 
cells begin to proliferate, reaching a peak at day 3, and infiltrate these 
parenchymal islands in order to fe-establish vascular supply (figure 4.4.1 ).83 
Normal hepatic weight and architecture is established by about day 8 m 
')'11 
murine models of 70% hepatectomy.'" 
The molecular mechanism for this induction of angiogenesis includes tbe 
'- ~ 
increased expression of VEGF, tbe angiopoietins (ang-l and -2), and their 
receptors (llt-l, nk··}, Tie-I and Tie-2) in the regenerating liver (figure 
4.1.3). The expression of VEGF and its receptors (nt-1 and flk-l) start 
increasing soon after liver resection, and peak at day 3, in parallel with the 
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peak in endothelial cell proliferation. Ang-2 expression precedes VEGF 
expression and remains elevated for 6 days.H3 This corresponds with 
previous studies suggesting that Ang-2, by inhibiting Ang-l and disrupting 
blood vessels, has an important role in initiating angiogenesis.1l1 
In contrast, Ang-l and the receptors Tie-l and Tie-2 have slow induction 
responses following liver regeneration and reach peaks at days 4 - 7. This is 
consistent witb the role of Tic- L in endothelial differentiation, maintenance 
of blood vessel integrity and the resolution phase of angiogenesis. 84 
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Figure 4.4.1 - Prolirerative responses of hepatoc)·t('~ ltnd endothelial cell~ 
following 70r:~ hep:ite·doJn). 
:al Pernntage of hepatocytes and endothelial cells in the 
proliferati'\'e state by BrdU uptake. 
b) The identification of proliferatjng enclothelJal ceJJs by doubl(' 
immunohistochemical staining. Rt."d nuclear staining denotes 
UrdU uptake, whjle the endothelial Jtl{'mbrane is s.tained brown 
using an antibody to RECA-l. 
(.) Arrowhead denotett a pmlilha1ing endothelia] cell nucleus. 
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Figure 4.4.2 - Ch;inges in bepatk archil~rtun during Uver 
regeneration. 
a) Pre-hepaloclom~' state showing that inl)st hepal(t(')'lts have at 
least one f:H'et of contact with an endothelial sinusoid. 
b) AI 3 days post hepaleclomJ. wide gaps .we noted bel~'een 
inlervening sinusoWs as hepatocyte proliferation outstrips 
endothelial proliferation (arrows). Normal hepatic arc·hitecture is 
rc-established b.~' wild-type in anjm;iLs b~ 8 days after 70% 
hepatectomy. Endothelial staining denoted by antibody raised 
a.gainsl rat endothelial cell antigen.! (RECA-I\. 
FigurE'S 4.4.1·4.4 .2 
Sato. T. el al. Sinu..<,oid;il endothdiaJ cell proliferation and ex-pression 0" 
angiopoietinffie famn)' in regenerating rat Ih'er . .I Hepatol. 34, 690-8 
(2001), Reproduced wilh perrnissJon. 
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Hel)(itic expression of angiogenic 
grlHvth factors f oHow i ug 70 % -
hepa1edomy, 
b) 
Norlhern blot itnaJ,ysis of 
angiogenic growth factor-s and 
growth fador receptor mRl\;A 
expr('ssion after 70%-
hepatectom)'. VEGF mRNA 
txp.ression peaked at 72 hours. 
whUe Ang-l peaked at 96 
hours, SignUicant increases in 
Ang-2 mRNA ,""ere aLf,;o noled,. 
'f\'ith peak h'\'ds signifkantly 
delayed ('ornpared "\'ith VEGF 
and Ang-l. All four r-eceptors 
were elevated after 
hepatteh)m)'. with fll-I. and 
then I1k-l, the first to increase. 
Bot.h Tie-I and Tie-2 WE'r(, 
elt'vatt'd, but their peak 
expressions coincided with the 
resoJution phase of 
angiogenesis . 
Graphic representation of 
angiogenic growth factor 
mRNA expression fl)lIowing 
70%-hepafedoml· 
c) Graphic representation of 
angiogenic grc)'wth factor 
receptor mRN"A exprt'SsJon 
following 70 % -hl"patrtlom)'. 
Sato. T, et aJ. SinusoidaJ endothelial 
('('11 proliferation and expression of 
a.ngiopoietin/l'ie "ami I)' in 
rl'generating tal lher, j Hqalo/. 34, 
690-8 1'20(1), Reproduced with 
permission. 
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4.4.2 Results and discussion 
Standard 7Wl() hepatectomy was performed on age-, sex- and type-matched 
wild-type and Cd39-null mice. 222 Mice were observed for mortality, and 
surviving mice euthanased and livers analyzed by immunohistochemistry at 
J 4 days. 
In keeping with previous stuclJes using the 70r;{J-hepatectomy model of liver 
regeneration. wild-type mice had no mortality and normal hepatic size and 
architecture was restored by day 8 (Sun Xiaofeng, unpublished data). 
Tn contrast, 30(Yc) of the Cd39-null mice died within the first few days after 
liver resection secondary to Inassive vascular thrombosis, haemorrhage and 
shock. It is our view that tbis occurred because of vascular perturbations 
and, in particular, platelet dysfunction in the Cd39-null mouse, and not 
because of defective angiogenesis. Previous work in the laboratory has 
shown that the Cd39-nulJ mouse has a major defect in platelet function and 
vascular haemostasis, probably secondary to platelet P2Y l desensitization 
and decreased aggregatory responses to ADP.IK4 
However, of the lTllCe that survived the initial vascular complications 
associated with hepatectomy, up to SW'!r) had persisting lethargy, anorexia 
and jaundice secondary to impaired liver regeneration (SLUl Xiaofeng, 
unpublished data). 
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At 5 days after 70(}f:l-hepatectorny, wild-type livers demonstrated both 
hepatocyte and endothelial cell proliferation, as evidenced by BrdU uptake. 
In contnlst, the Cd39-null animals had normal hepatocyte proliferation, but 
limited endothelial cell proliferation (figure 4.4.4, a-b). Also, Tune] staining 
for apoptosis showed that there was marked endothelial cell apoptosis in the 
Cd39-Tlul], but not in the wild-type mice (figure 4.4.4, c-d) (Sun Xiaofeng, 
unpublished data). 
This combination of poor endothelial cell proliferation and enhanced 
apoptosis in Cd39-null mice following liver resection, resulted in the failure 
to re-establish normal hepatic sinusoidal architecture and the persistence of 
I avascular blands of hepatocytcs up to 7 days (Fig 4.4.5). In other words, • 
• despite normal hepatucyte proliferation, liver regeneration in Cd39-null mice· 
I was impaired because of defective angiogenesis. Whereas wild-type mice re-
I established normal hepatic archhecture by 8 days, in Cd39-null mice, late 
1 1, " 'j' db' I d (" I . l' . • lver Il1Jury, as rnanreste· y Jsan s 0 1SC laerTIlC lepatlc necrosls, were 
I seen up to 14 days after resection (Fig 4.4.6) (Sun Xiaofeng, unpublished 
I data). 
I Tbese results demonstrate that normal Cd39 function is required ror 
I physiological angiogenesis during liver regeneration. 'fhis prompted further 
I research into the role of Cd39 deletion in patho-physiologiC::11 angiogenesis 
\ following experimentalrnyo~~l!dial infarcti()L _I 
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Figure 4.4.4 - Graphs representing the proliferation 01' hepatoc)'tes 
(a) and endothelial teJls (b) in wild~type and Cd39-ilUll endothelial 
cells al'ter 70t,1,·hepate<'tomy. There is simiJar proliferation 01' 
hepatocytes (a) in Cd39-null mice, but markedly dec'reased 
endothelial cell (b) proliferation. compared with wild-t)'pe mice. 
llar charts represent the 3\'erage number of BrdU-posWve 
hepatoeytes (a) or endothelJal reUs (I» per high-powered field 
(hpi). *. P<O.OS. (Sun Xiaofeng, unpublished data). 
C Wiid-type 
• Cd39-nliil 
DWild-type 
.Cd39-nult 
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Figurt 4.4.4 (c) 
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Figure 4.4.4 (d - Graph representing endothelial cell apoptosis in 
wild-t)'pe .md Cd39-nulJ endothelial ceJIs after 70C/~ -hepatec(ortl)'. 
Betw€t'n days 5 and 7, there is marked apoptosis of Cd39-null, but 
not wild-type, endotheJial reUs. Bar charts represent the 3\'erage 
number of apoptotk endotheltaJ cells per high-powered field (hpfl 
by Tunel staining, *, P<O.05. (Sun Xiaof'eng. unpublisht'd data). 
F'igure 4.4.4 (dl 
Figure 4.4.4 (d) - Tunel Stain showing endothelial cell apoptosis in 
regenerating CdJ9-nuli mouse li~'er 5 da)'s after 70%-
hepatt'ctomy. Minimal apoptusis was noted. in wjld-t)'pe li\!er~, 
(Sun Xiaofeng, unpublished dala). 
o Wlld-t~'pc 
• Cd 39-null 
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Wild-t~'pe Cd39-nuJJ 
Figure 4.4.5 - ClHI-staining of endolhelial ('elJs at da)' 7 post 70%-
hepaledomy in wild-type and CelJS/-null mke. \Vild-type mice 
~hows normaJ hepatic architecture with eath hepatocyte Itu\'ing at 
Ie.ist one facet of contact wjth the sinusoidal endothelium (lell). 
CdJ9-llol1 mouS(> has wide. irregular g ps ~tween adjacent 
sinusoidaJ and s.eH'n"tl hepati)('ytes lack ('Imtad with the 
vasculature (righil. (Sun Xiaofeng, unpublished data). 
CdJ9-nuH 
Figure 4.4.6 - Wild-t)'pe and Cd39-nuJI U\'er ~ttions at da)' 14 
after 70%-hepateC'tomy. "Iild-type sho\\'s normal architecture 
(left), .... 'hile cd39-nuJI Ita\'e Jarge areas of hepatk net.' ro si. .. 
secondary to cJefee-tin' revase-uLarizatio-n (right). Apoptolic areas 
.ire denoted b)' brown "fund staining. (Sun Xiaofeng. unpublished 
data). 
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4.5 JVIYOCARDIAL INFARCTI()N 
4.5.11ntroduction 
IIcarl disease, in particular ischaemic heari ctisea~e, remains the major cause 
of death in western societies. 221 As a novel approach to the treatment 0[' this 
disease, several researches have attempted to use pro-angiogenic therapy to 
induce myocardial collateral formation and increase myocardial blood flow. 
At least 17 clinic;}] trials of myocardial angiogenesis have been performed to 
date, involving over 900 patients, Despite initial promising results in non-
randomized trials, none or the double-blind randomized trials showed 
clinical benefits. However, newer approaches like gene therapy may yet 
prove useful as treatments for ischaemic heart diseasc. 224 
It is with this in mind, that the role of Cd39 deletion was studied in a murine 
model of myocardial infarction. 
4.5.2 Methods and results 
The left anterior descending coronary artery was ligated in wild-type and 
Cd39-nul1 mice (11.=5,5), inducing massive Infarction of the anterior left 
ventricle. After recovery, the mice were monitored daily and the surviving 
mice euthanased at 2g days. Myocardial tissue was examined by 
i Il1munohistochemistry following spontaneous death or euthanasia. 
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Figure 4.5.1 shows the survival curve of wild-type and Cd39-nul1 mice after 
myocardial infarction. Within 4 days, two-thirds of the wild-type mice had 
died because of cardiac rupture (Mika Ogawa, unpublished data). This 
correlates with previous work showing that myocardial rupture, occurring in 
the firsl 4 days, is the commonest cause of death following experimental 
myocardial infarction. lOt Almost uniformly fatal, cardiac rupture causes 5 to 
31 of all in-hospital mortality following acute myocardial infarction in 
hurnans. 225 
However, no Cd39-null mice died of cardiac rupture and Cd39-nul1 mice 
initially had a survival benefit over their wild-type counterparts. But, from 
one week after myocardia] infarction, Cd39-nul! mice started to die of 
progressive cardiac failure and at 4 weeks had similar mortality rates to 
wild-type mice. The Cd39-null mice that died exhibited congested, 
oedematous lungs and livers. No wild-type mice died of cardiac failure 
(Mika Ogawa, unpublished data). 
Histological examination of hearts from wild-type and Cd39-null rrllce 
demonstrated that CD45-positive inflammatory cells failed to migrate into 
Cd39-null infarcts (figure 4.5.2). The CD45 antigen, also known as 
leukocyte common antigen (LCA), is a tyrosine phosphatase expressed by 
all cells of haematopoietic origin, with the exception of red blood cells and 
platelets. 22h In addi tion, the migration of CD31-positi ve endothelial cells into 
Cd39-null infarcts was significantly decreased. Post-infarct myocardial 
healing in Cd39-null mice was thus characterized by poor inflammatory ceH 
inri1tration of the necrotic myocardium and defecti ve angiogenesis during 
myocardial remodel ing (Mika Ogawa, unpublished data). 
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4.5.3 Discussion 
The ex.planation for the unusual finding that Cd39-null mice have decreased 
cardiac rupture but increased cardiac failure following experimenuil 
infarction is that this inflammatory cell infiltration and revascularization is 
both beneficial and detrimental following myocardial infarction. 
On the onc hand, revascularizalion is required for myocardial remodeling 
aftcr myocardial infarction. Without remodeling, the mice develop to 
progressive cardiac failure and die. On the other hand, during 
revascularization and remodelling, the extracellular matrix within the infarct 
must first be digested. Inflarmnatory cells and endothelial cells migrate into 
the infarct and secrete a range of extracellular proteases including the matrix. 
metalloproteinases and the plasminogen activator-pJasrnin family of 
proteases. These proteases weaken the infarcted myocardial wall and 
predispose to cardiac rupture. 
In keeping with this hypothesis, infarcted myocardiaJ tissue from Cd39-nulJ 
mice had significantly lower levels of gelatinase metalloproleinase (MMP-2 
and MMP-9) activity, than wild-type infarcts (data not shown). We believe 
that this decrease in protease activity occurred because of the failure of 
inflammatory and endothelial cells to migrate into the infarct rather than 
because of an actual decrease in matrix metalloproteinase production. We 
have shown, for example, that there is no difference in the production of 
MMP-2 and MMP-l) by wild-type and Cd3LJ-null endothelial cells in vitro 
(chapter 5.6). 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
CD45 
CD31 
Wild.t)'p(' (,(/39-n uJJ 
F'igure 4.5,2 - Immunohistochemical staining or infarcled m)'ocardial 
tissu(' from wiJd-tJPe (Il'ft) and CdJ9·nuU (right) mice. Th(' uppt>r panels 
show in(T('ased migration or CD4S-positive inIhnnmatory cells into wild· 
t)'Pe (Iefl) , compart'd with Cd39-null (right), infarcts. Similarl~'. new 
blood \'esseb formation larrows. C031-posilh'e ('ndolheliaJ c('lls) .is noted 
~' ithin infarcted tissue in wild-type luarts (left, lower panel). Few new 
blood vessels de\'('loped in Cd39-nuJl infarcts (right. lower panel). (Mjka 
Ogawa, unpublished dala). 
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The beneficial and detrimental effects of myocardial remodeJin o after _ c 
myocardial infarction was confirmed in another study usin cr oenetica1Jy 
b b 
engineered mice. The urokinase-type plasminogen activator knock-out 
mOllse (u-PA-/-) was compJetely protected, and gelatinase-B (l\/[MP-9)-null 
mouse partia1iy protected, from cardiac rupture following acute myocardial 
infarction. But, like the Cd39-nul1 mice, the u-PA-/- mouse showed impaired 
infarct revascuJarizaLion and developed fatal cardiac ischaemia, arrhythmias 
and cardiac failure. 101 
The question remaining is, could we limit matrix digestion sufficiently to 
prevent cardiac rupture, but still allow myocardial remodeling after acute 
myocardial infarction? The researchers involved in the abovl~ study were 
able to show that temporary administration of plasminogen-activator 
inhibitor-I (PAf-l) or the matrix metalloprnteinase inhibitor TfMP-l 
protected against cardiac rupture without compromising remodeling. 101 This 
shows, at least in an animal model, that temporary angiogenesis inhibition 
could have therapeutic benefit in preventing cardiac rupture after acute 
myocardial infarction. 'r11is would certainly prove a novel and unexpected 
use of anti-angiogenesis therapy. 
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4.6 'TUMOUR ANGIOGENESIS 
4.6.1. Introduction 
The importance of angiogenesis in faciiilating the growth of tumours has 
been stressed earlier in this dissertation. Understanding the precIse 
molecular mechanisms involved in the complex process of tumour 
angiogenesis is required to realize the ultimate aim of developing effective 
anti-angiogenic cancer therapies. 
Deletion of Cd39 is associated with defective angiogenesis in experimental 
models of liver regeneration and myocardial infarction, implying that 
tumour angiogenesis may also be impaired. For this reason, the effects of 
Cd39 deletion on in vivo experimental models of angiogenesis were 
examined. 
4.6.2. Methods and results 
C57BLl6X 129svj strain wild-type and type-matched Cd39-null mIce were 
inoculated with 3.0 X lCi' cells 13 J6-F 10 melanoma (13 16-FlO, ATCC: CRL-
6457, n=8,6), B J6-CG (stable p-BCG expression vector transfected) 
me1anoma227 (n=5,4) or LLC cells (LLC, ATCC: CRL-1642, n=4) into the 
dorsal subcutaneous space. Tumour size was measured daily and the tumour 
volume calculated using the formula V=JtL. \"12/6, where L is the longer 
diameter, and W the short diameter. 
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The urine of mice inoculated with B 16-CG melanoma cells was collected as 
described,·:27 and urine ~-HCG and creatinine measured Llsing a free 11-r-fCG 
ELISA Kit (Alpba Diagnostic, Texas) and a Creatinine Kit (Sigma 
diagnostics, Inc. St. Louis MO), respectively. 
Wild-type and Cd39-null mice were also injected with 5.0 X 101 B 16-F I 0 
melanoma into the subperitoneal plane of an abdominal wall /lap. The 
tumours were examined at 2-day intervals, the tumour size measured and 
new blood vessels growing into the tumour were counted by microscopy. 
After ]5 days, both groups of mice were sacrificed and the tumours analyzed 
by immunohistochemistry. 
i) Sub(:utaneous tunlour growth 
Since angiogenesis has been shown to be impaired in Cd39-null mice during 
liver regeneration and post myocardial inl'arction, the effect of deletion of 
the bulk of vascular endothelial cell NTPDase activity on transplanted 
tumour growth was studied in vivo. Matched wild--type and Cd39-null mice 
were injectcJ subcutaneously with murine melanoma or lung carcinoma 
cells. Lewis lung carcinoma is a cell line established from the lung of a 
C57BL mouse, which was implanted with primary Lewis lung carcinoma. 22R 
The cell line is highly tumourigenic in C57BL mice, but seldom 
spontaneously metastatic. However, it is orten used in experimental models 
of metastasis by intravenous injection of tumour cells. 22 ') B 16-F 10 lS a 
murine melanoma ce]] line, which is tumourigenic in C57BL!6J mice.20<) 
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As predicted, the growth of both 13 16-FJ 0 melanoma and Lewis lung 
carcinoma was significantly attenuated in Cd39-null mice (figure 4.6.1). 
Wild-type mice had significantly larger B 16-Fl 0 (figure 4.6.2, a) and LLC 
(figure 4.6.2, b) tumour volumes at one week after inoculation. Tumour 
growth then entered the exponential phase in wild-type mice, in keeping 
with the induction of an angiogenic pflCnotype. In contrast, tumour growth in 
Cd39-null mice was severely retarded to ]5 days (Tomokazu Hoshi, 
unpublished data). 
The release oC /:i-BeG following implantation of B 16-FIO melanoma cells 
stably transfected with f3-HCG vector (B 16-CG) was also used to estimate 
tumour voluOle. 227 f3-BeG excretion correlates well with tumour volume in 
this model (R2=:0.96, data not shown). Daily urine f)-HCG excretion was 
significantly decreased in Cd39-null mice, in keeping with the observed poor 
tumour growth in these animals (figure 4.6.3) (Tomokazu Hosh i, 
unpublished data). 
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figure 4.6.1 - Repre.sentalh'e examples of tumour growth in wild t)'pi." 
(left) and CdJ9-huU (right) mil-e al 1 days aft~r impluntation. The uppi."r 
lumour i~ Lewis lung ('arcinoma and thl' lower is BI6-F'lO melanoma. 
(Tomokam Hoshi, unpublisht.'d data). 
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Figuh' 4.6.2 - l\'Ieasurement of mlli'ine B16-FlO (a) and LLC Cb) 
subeutaneous tumor growth in wild type (0) amI Cd39-null (.) 
mice. Bars show mean tumor volume in mmJ ~ s.Ld. *, P<:O.OS. 
(Tomokazu Hoshi, uJiPubJished dat~l~. 
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Figure 4.6.3 - ~HCG excretion rollowing subcutaneous jno~ulation with 
D16-CG tumors. \Vild typl:' ~n), CdJ9~uli (.). Bars show urinary ~­
HCGlcrNllinine (mIL/mg) :t s.t.d. '" 1'<0.05. l'J'omokazll Hoshi, 
unpublished data). 
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ii) Subperitoneal tunumr growth and direct visualization of 
angiogenic vessels. 
Inoculation of B 16-1::"10 tumours into the subperitoneal abdominal wall 
allowed direct observation of tumOLlr growlh. Direct visualization of' B 16-
FlO tumours in wild-type and Cd39-null animals 7 days after implantation 
confirmed pnor tumour growth in ('d39·-null mice (figure 4.3.4). in additioll, 
this model allowed direct visualization or new vascularization of the tumour 
by dissection microscopy. By 2 days after tumour injection, wild-type mice 
had evidence of new vessels infiltrating the tumour and the number of 
vessels increased steadily over the next week (Fig. 4.3.5). This did not occur 
in Cd39-null mice, in keeping with our hypodlesis that defective 
angiogenesis is responsible for the observed decreases in tumour growth 
n'omokazu Hoshi, unpublished data). 
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Figure 4.6,4 
WIld-type Cd39-null 
Figure 4.6.4 - Ma("roscopit ap~arance of suhperitoneal lU6-FIO 
tumor al 1 ua:o-'s after implantation in '<4'iJd ty~ (left) and CdJY-null 
(right) mice. VisuaJjzatlon under light microscoPJ allowed the direct 
counting of angiogenic blood vessels in"'ading the tumour. 
((Tomokazu Hoshi, unpubUs.hed data). 
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Figure 4.6.5 - Vessel count., in sub)X'ritoneal 816-1'10 tumors in ""ild 
tJpe (0) and Cd39-null ~.) mice. Bars show mean number of vessel<; 
:t s.e.m. *, P<0.05. (fomokazu Hoshi, unpuhlished dala). 
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were largely devoid of vasculatLLre, basal lamina divided individual tumour 
cdJ nests into gland-like structures (*). Similar encasement of tumour cells 
by basal lamina was absent in tumours in wild-type mice (figure 4.6.6, g) 
indicating a higher level of tumour cell differentiation in tumours in Cd39-
null mice. In addition to enhanced growth. tumours in wild-type mice were 
capable of invading the underlying dermal muscle fascia (*, figure 4.6.6, i). 
In contrast, in tUlllOurS grown in Cd39-nuU mice (j), tumour cell invasion 
was absent and the tumour mass and muscle layer (*) was clearly separated 
(figure 4.6.6, j) (Christian Sundberg, unpublished data). 
Maturation of angiogenic tumour vasculature requires the recruitment of 
pericytes and smooth muscle ceUs around the inGltratlng endothelium. In 
tumours implanted into wild-type mice, endothelial cells (blue) were 
partially enveloped by pericytes (green) and surrounded by interstitial 
fibroblasts (red) (arrow, figure 4.6.7, d). fn contrast, tumours in Cd39-null 
mice were devoid of endothelial cells, pericytes and fibroblasts, indicating 
pluripotent cellular migration defects in Cd39-null mice. Pericyte-enveloped 
vessels were confined to the adjacent normal tissue (arrow, figure 4.6.7, h). 
Markers of blood vessel activation such as dissolution of the enveloping 
basal lamina, increased pericyte expression of NG2 ami PDGFf)-receptors, 
decreJsed pericyte expression of smooth muscle <x-actin, and increased 
endothel ial expression at' VEGFR2-receptors was apparent in vessels at the 
interface between tumour and normal adjacent tissue in wild-type but not in 
Cd39-llllll mice (Table 4.6.1). Platelet (green) and l'ibrin (red) deposition, 
central components of tlle provisional pro-angiogenic matrix was noted in 
and around infiltrating vessels in wild-type tumours (arrow, figure 4.6.7, I), 
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hut in Cd39-null nuce was confined to the rim of tissue surrounding the 
tumour (arrow, figure 4.6.7, p). Thus, despite deposition oC a provisional 
matrix in normal tissue adjacent to tbe tumour, blood vessels failed tu 
appropriateJy activate and migrate into the tumour mass in Cd39-null fmce 
CTable 4.6.1) (Christian Sundberg, unpublished data). 
These results confirm that tumour angiogenesis is defective in the Cd39-nuU 
mouse. The failure to adequately vascularize implanted tumours resulted in 
significantly decreased tumour growth in ('d39-null animals. 
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endothelial cells 
F4/BO-positive 
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Integrin U llb-
positive platelets 
Perlecan-positive 
basement lamina 
Trichrome stain 
Figure 4.6.6 - Immunohistochemistry staining of implanted tumours in wild-type and 
Cd39-null mice. Bars=20~m. (Christian Sundberg, unpublished data). 
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m8lKe<r 
Smooth 
mUllC.Ie< 
Q-sclln 
CO:JI+ 
endotnellarl 
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compoa;lle 
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Inti!'glin tt"e 
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~I" 
oompa.site 
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Figure 4.6.7 - Triple immunofluorescent staining of implanted tumors. 
Tumors grown in Ih(' suiK:utaneolls space in\\'i1d Iype (a-d, i-I) and Cd39-nuJl 
(e-)" mop) mice with antibodies reeogniljng; perkYles and fibroblasts (pan-
rt'lkuJar I1llroblast marker:t ~a,e): perieytes and smooth muscle ('ells fsmoolh 
muscle a ;,ictin) (btl): fibrjn (i.m); platelets (integrin U llb ) (j,n): endothelial 
cells (CD31) ie, g, k will 0) and their l'ompositf.'s (d, h. I and p). The doth>d 
while line delinf.'ates tlu> inlerf'a{'e between the tumor mass and adjacent 
normal tissue. The smalJ arrow indkates the dirf.'c(ion of th(' twnor. 
Solid bars=20tun. (Chrblian Sunbf.'rg. unpublished data.). 
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Table 4.6.1. 
Distrihution 01' cell-type specific markers. cellular activation markers and extracellular matrix compmll~nls 
in wild-type and Cd39-null mice fullowing tllmour implantation (Christian Sundberg. llll[Jublished dara), 
Eruilltb eli lEn 
PECAM·l 
Wild,ly!',., 
C"3Q-Null 
Pancndothelial Marker 
Wild type 
Cd3Q-llull 
VEe; FlU· receptor 
Wild-lype 
Cd3()'illrlJ 
J'-,ri,Y1h!5jJY)YQfillJ:nI)lcl~t~ 
C!·SMA 
Wikl·,yp.: 
CrLN-liull 
I'DGF~·rcn·plors 
Wild-lyp" 
CJ39-111111 
NG2 
Wildlype 
Cd.N-l\ul! 
RetkularFihroblasts 
Wild-type: 
('d3Q,null 
lIilSill Lamina 
I'erlecan 
Wild·type 
(,,139'l1ull 
Fibrin 
Wild-type 
Cd39 null 
Illtlllmlllilt'lry (,ell~ 
F4/80 
Wild-type 
C/3<J'l1ull 
Platdels 
Wild-type 
CUlJ'llull 
H-cdls 
Wild-type 
Cd3'i-l1ull 
T-cells 
Wild-Iypl~ 
Cd.N-null 
Granulocytes 
Wild-type 
CdJ9-null 
Normal 
Dermis 
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Key: - = n() expression. + c= sparse expression. ++ = abundant expressi[)n. NA," 110[ applicable . 
.. I =, ,Issociated with vascul:lture and muscle bundles. "<! associated with tumour nests. 
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4.6.3 Discussion 
T'hese results suggest that abnornwl purinergic signaling in the Cd39-l1ull 
vasculature results in profound defects in tumour growth and angiogenesis. 
This is consistent with the finding of defective angiogenesis during liver 
regeneration and aiter myocardiallnfarction in Cd39-null mice. 
Cd39-null mice exhibit the normal initial phases of angiogenesis, including 
rnotber vessel formation, increased vascular permeability and fibrin 
deposition. llowever, there is a profound defect in the migration of 
endothelial and ini1ammatory cells into tumours in Cd39-l1ull animals. There 
is also abnormal resolution of angiogenesis in C'd39-nul1 mice characterized 
by poor recruitnlent of surrounding pericytes and smooth muscle cells to 
new blood vessels. As embryonic vascular development is normal in Cd39-
null miceP1!j, this data suggests that purinergic signaling has dlfferential roles 
in physiological blood vessel development as opposed to pathological 
. . 
anglOgencsls. 
Perhaps most importantly, these results suggest that pharmacological 
ectonucleotidase blockade may have a novel therapeutic role in clinical 
oncology practice. 
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4.7. TUMOUR METASTASIS 
4.7.1. Introduction 
Angiogenesis is crucially important in the process of tumour metastasis. Tn 
addition to allowing tumours to grow, cancerous cells can enter angiogenic 
blood vessels and travel in the circulation to distant organs. The 
development of twnour metastases correlates with increased vascularity of 
the primary tumour, and, at least in animal models, anti-angiogenic therapy 
prevents both tumour growth and tumour metastasis. This suggests that the 
angiogenesis defect of the Cd39-null mouse could also result in decreased 
tumour metastasis in these animals. 
AlthougYh an increased number of tumour cells enterincr the circulation to 
generally correlates with increased metastasis, the vast majori ty of 
circulating cancer cells are eliminated before seeding by immune and 110n-
immune det"ense mechanisms.23u A I em primary breast cancer can release 
up to HY' cancerous cells into the circulation per day,211 but very few of 
these ever become clinically significant metastases. 
The first possible explanation for this IS that endogenous angiogenesis 
inhibitors prevent the growth of those cancerous cells that do establish 
distant micrometastases. Anti-angiogenic factors released by the primary 
tumour include angiostatin and endostatin and these may prevent the growth 
of micrometastascs. 
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There is also much evidence linking haemostatic factors, in particular 
platelets and fibrinogen, to increased tumour cell survival in the circulation. 
Platelet activation is thought to facilitate tumour metastasis by, inter alia, 
protecting circulating tumour cells from natural killer (NK) cell-mediated 
el imination.2J
1 
It was initially expected that the Cd39-null mouse would have greatly 
increased platelet acti vation and that spontaneous thromboses would develop 
because or decreased hydrolysis of pro-aggregatory ADP. However, deletion 
of Cdll) was associated with a mild bleeding diathesis and poor platelet 
acLi valion m vivo and in vitro. The demonstrated explanation is that 
decreased ectonucleotidase activity causes excess intravascular ADP 
concentrations and desensitization of the major platelet ADP receptor, 
P"Y lXf 
"-' I' 
Increased fibrin deposition has also been noted in the pulmonary, renal, 
cardiac, cerebral and splen ic vasculature of Cd39-nuH mice. IH4 This probabJ y 
represents activation of secondary hemostatic responses by activated 
endothelial cells in Cd39-null animals. 
The Cd39-null mouse thus provides an interesting model for studying 
tumour metastasis because it has defects in both angiogenesis and in platelet 
acti vation and fibrin deposition. This decreased platelet function could cause 
decreased survival of circulating tumour cells in Cd39-null mice, while 
defective angiogenesis could prevent the growth of those tumour cells that 
did form micrometastases, Both factors would tend to limit the formation of 
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metastatic tumours. On the other hand, increased fibrin deposition would 
tend to increase the formation of micrometastases. 
4.7.2. Methods and results 
Because B16- FlO and LLC tumours seldom form tumour metastas is 
spontaneously after subcutaneous implantation, tumour cells were injected 
directly into the inferior vena cava and the mice observed for the 
development of pulmonary metastases. 1 x I 05 ceUs LLC or 1.5x lO5 B 16-F 10 
cells were injected into the inferior vena cava of C57BL/6X129svj strain 
wild-ty pc and type-matched Cd39-l1ull mice. After 17 days the mice were 
euthanased and the pulmonary metastases anal yzed for size and number. 23~ 
Wild-type lungs became massively infiltrated with metastatic melanoma and 
lung carcinoma and, at 15 days after intravascular injection, tumour 
metastases had replaced the entire lung (figure 4.7.1). In contrast, Cd39-null 
lungs had limited tumour loads. Wild-type lung weights were also 
significantly increased over Cd39-null levels. (1738 ± 276 mg wild-type vs. 
604 ± 42 mg Cd39-nu11. P<O.O 1 (Fig. 4.7.2)) Cfomokazu Hoshi, unpublished 
data). 
T'o study the effect of apyrase on tumour metastasis, O.3xl05 B 16-FlO cells 
plus or minus O.2U/g soluble apyrase (grade vn apyrase, Sigma-Aldrich, 
Saint Louis, MOl were injected in the inferior vena cava of wild-type and 
Cd39-null mice. After 13 days, mice were euthanased and surface metastatic 
foci counted. In keeping with the increased in lung weights ill wild-type 
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animals, 15 days after intravascular inoculation of O.3xl05 B16-FIO cells, 
the number of visible surface metastases was significantly greater in wild-
type versus Cd39-null mice (205 ± 12 wild-type vs. 74 ± 62 Cd39-null. 
P<O.05). 
The addition of apyrase, a soluble NTPDase, with the tumour cells at the 
time of inocu lation, irKreased the number of visible metastases in both wi [d-
type and Cd39-nuH mice (figure 4.7.3). The nmnber of metastases increased 
by 6 (Y?'lJ in wild-type (205 ± 12 willi-type VS. 331 ± 33 wild-type plus 
apyrase, P<O.(2) and by almost 300% in Cd39-nuJl animals (74 ± 62 C'd39-
null vs. 2H2 ± 37 Cd39-null plus apyrase. P<O.O(5). Importantly, there was 
no significant difference between the number of metastases in wild-type and 
Cd39-null mice after addition of apyrase (331 ± 33 wild-type plus apyrase 
vs. 282 ± 37 C'd39-null plus apyrase. P>O.I) (Tomokazu Hoshi, unpublished 
data). 
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Figure 4.7.1 
Wild-type 
Figu.r(' 4.7.2 
* 
B16-Fl0 
LLC 
Cd39-null 
Figure 4.7.1 
Repre~ntaHvr examples of 'wild typt' (left) and 
CJ39-null (dghO mouse lungs at 15 days after 
tumour inje<:-lion. Vppt'r paneJs are of BI6-FlO 
melanoma metastases, and lower of Lewis lung 
tardnoma metastases. (Tomoka2u Ho .... hi, 
unpubljshed data). 
(i'igure 4.7.2 
\Vild I~'pe (0) and C1139-null (.) lung weights 
IS days after i.ntra'l'enous tuitwur injedion. 
Mice were injet'too wjth 1.5xlO~ Bl6-FlO cell .. 
per 2Sg bod)f-weight jnto tJle inferior ... ·ena C3\'3. 
fiars represent m~an ",'eight ± s.e.m. *, P<U.006. 
(Tomokalu Hoshi. unpubJish('d datal. 
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Wild-type Cd3~null 
F'igure 4.7.3 - Rt.'preM'ntative examplt'S of wild type. (je(l) and 
Cd39-noll (righl' mouse lungs al IS days aftt'r B16-FIO tumour 
injection. Lower panels show the effed of apyrase ""hUe the 
upper pant'ls repreSt'nl control experiments. (Tornokazu Hoshi, 
unpubHsht.'d. data). 
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4.7.3. Discussion 
Angiogenesis is required for the growth or both primary and metastatic 
tumours, alld the lack of tumour metastases may renect the angiogenesis 
defect of the Cd39·-null mouse. In addition, platelet activation has been 
shown to facilitate tumour metastasis by protecting circulating tumour cells 
f'rorn NK cell-mediated elimination.2J2 It bas previously been shown that 
deletion of Cd39 results in platelet dysfunction, because of P2Y j receptor 
desensi tization secondary to increased pericellular nucleotide 
cOflcentrations. IX4 Platelet dysfunction in C'd39--null mice would render 
intravascular tumour cells more prone to immunological elimination and 
may further explain the decreased development of pulmonary metastases in 
Cd39-11UIl nlice. 
'This does not explain ho'vv the addition of soluble apyrase at the time of 
tumour inoculation increases the number of tumour metastases in Cd39-nulJ 
mice to wild-typeleve[s. A single dose or apyrase should not be sufficient to 
correct platelet function in Cd39-null mice in vivo. 
Perhaps the most Likely explanation is that apyrase modulates integrin 
activation states on the tumour cells themselves prior to injection and that 
these integrins facilitate binding to the pulmonary vasculature and the 
establishment of micrometastases. 
rf this is the case, it has important implications for the development of 
cctonucleotidase-baseci therapies. Soluble derivatives of CD39 have been 
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proposed as effective anti-thrombotic or anti-inflammatory therapies,2J4 but 
our findings suggest that these may also increase the growth and/or 
metastasis of tumours. 
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CHAPTERS: 
NOVEL ILXPERIMENT AL MOD_El.JS 
I)EI-"'E~rION OF Cd39 RI~Slll/rS IN V ASClJl.JAR 
IN1'EGRIN DYSFlTNC~rION INVI1'RO 
Deletion or Cd39 is associated with in vivo defects in both physiological and 
pathological angiogenesis. This results in abnormal angiogenesis in 
Matrigel n ! plug, liver regeneration and myocardial infarction rnodels of 
angiogenesis. With important therapeutic implications, deletion of Cd39 also 
results in the decreased growth of both implanted and metastatic tumours. 
Angiogenesis is known to in valve several stages. Firstly, vessels dilate and 
become leaky in response to VEGF. This allows extravasation of plasma 
proteins, which form the provisional scaffold for endothelial migration. 2 
This initial stage was preserved in Cd39-11UlJ animals undergoing 
angiogenesis in MatrigcrlM plug and implanted tumour experimental models. 
In fact, increased fibrin deposition has been noted in tbe tissues of Cd39-null 
animals. liI•1 
Secondly, enuothelial ceJls must proliferate and migrate towards the source 
of the angiogenic stimulus." This migration is dependant on the action of 
extra-cellular proteases, including matrix metalloproteinases.'lj Cell matrix 
receptors like integrin (x v I3, and (Xvf3s are also crucial mediators of 
endothelial cell migration.]'l 
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Finally, endothelial cells must form mature blood vessels in a process that 
requires endothelial tube formation, production of a new basement 
membrane and the recruitment of pericyles and smooth muscle cells around 
the new endothelium. 2 Excessive vessel formation is controlled by the 
induction of endotbelial aportosis. Several growth factors, in particular 
VEGF, rromote enclothelial survival, while many angiogenesis inhibitors, 
both endogenous and exogenous, promote endothelial apoptosis. 1 Close 
interaction between endothelial cells and pericytes protects endothelial cells 
from apoptosis following growth factor withdrawal. J5 .30 
In order to further characterize the angiogenesis defect of the Cd39--null 
mice in vitro, we established primary endothelial cell cultures from vvild-
type and Cd39-null mice. We used these endothelial cells to model each of 
the above angiogenic steps in vitro. In particular, we stllClied the proliferative 
responses, resistance to apoptosis and production of matrix 
metalloproreinase of wild-type and Cd39-null endothelial cells. We also 
studied integrin activity in wild-type ,md Cd39-null endothelial cells, with a 
particular ['oells on integrin o.vl3y 
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5.1 ISOLA'rION ()F' MURINE PULMONARY 
END()THELIAL CELLS 
5.1.1 Methods 
a) Solutions needed 
• PBS/Heparin: J unit heparin/ml 
• Endothelial Cell Media: 
• O. I (/{J Collagenase: 
200 ml I-lam's F-12 
200 ml DMEM OOW glucose) 
100 ml Fetal Bovine Serum 
Penicillin: Final concentration 100U/ml 
Streptomycin: Final concentration lOO~,tg/ml 
L-Glutamine: Final concentration - 2mM 
Endothelial Mitogen: 25mg 
Heparin: 50mg 
Filter Sterilize and store at 4 DC 
J63 
Prepare 0.2 collagenase (Worthington type 1) in 
50ml PBS with Ca:?+/Mg2+ 
Autodigest at 3rC for I hour. 
Dilute to 0.1 in PBS with Ca2+/I\1g2+ 
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Filter Sterilize and store at 4°C 
b) Preparation of antibody-conjugated heads 
II N cgati ve Selection Beads: 
.. Positive Selection Beads: 
I Oftl rat anti-mouse anti-FcyIII/Il antibody 
50ftl sheep anti-rat IgG dynabeads 
500Itl PBS (with 2 FBS added) 
t O,UJ rat anti-mollse lCAIvi-2 antibody 
50ft! sheep anti-rat IgG dyoabeads 
500,u1 PBS (with 2 FBS added) 
II Incubate antibody-bead conjugates overnight at 4°C. 
164 
.. Before usc, wash three times in PBS (plus 2 FBS) by repeatedly 
placing the beads in the magnet, aspirating the supernatant and 
resuspending the beads in 8m] PBS (plus 2% FBS). 
c) Tools required 
.. Surgical I Dissecting tools 
III J 4-gauge blunt cannula 
.. 140~tm sieve 
III 10 ml syringe 
.. 25-gauge needle 
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d) Isolation of murine puhnonary endothelial cells 
Three age-, sex- and genotype-matched mice were used per preparation. The 
ideal age is 8-13 weeks old. 
i) DAY 0 
• The mice were anaesthetized by sub-peritoneal injection of avertin 
(20mg/ml) and euthanased by cervical dislocation. 
• Avertin stock solution was prepared by dissolving 5g 2,2,2-
Tribromoethanol in 5ml 2-methyl-2-butanol, and diluting the solution 
to a final volume of 200ml. 
• Prior to dissection, the mouse was cleaned with 70% ethanol and the 
chest cavity opened. 
• The lungs were perfused with approximately 8 rnl of cold 
PBS/Heparin solution. This is done by injecting the solution into the 
right ventricle and cutting the left atrium to allow drainage of perfused 
liquid. 
• The lungs and heart were collected into cold Ham's F- 12. 
• This procedure was repeated for each of the three mice. 
The following steps were performed under the tissue culture hood 
• Two lOem tissue culture dishes were opened and 10 ml 7()c;'Ic) ethanol 
aliquoted into the first dish and 10 ml endothelial media into the other. 
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• The lungs and heart in Ham's F-12 were poured into a lOcrn tissue 
culture dish. 
• The individual lung lobes were dissected away from the heart, dipped 
briefly in 70 ethanol and then placed into the media. 
• Once all the lung pieces had been collected in media, all the tissue 
pieces were moved to a dry tissue culture dish. 
• The tissue pieces were minced into very small pIeces usmg sharp 
dissection scissors, aiming for a patCimousse consistency. 
• The minced tissue was transferred to a 50ml tube and digested for 
hour in 15ml 0.1 % collagenase at 3rC. The tube was shaken 
occasionally to aid the digestion process. 
FoUowing digestion, the samples were returned to the tissue culture hood 
• The digested tissue was homogenized by repeatedly drawing the 
collagenaseitisslle mixture through a blunt 14-gauge cannula. Aim for 
about 5-10 slow passages to avoid over-homogenization. 
• The mixture was filtered through the 140~tnl sieve into a lOcm tissue 
culture dish. 
• The filtered cells were collected in 20ml endothelial cell media and 
spun down at 1200 rpm at 4°C for 5 minutes. 
• The supernatant was carefully aspirated and the peJlet resLlspended in 
12m] endothelial media. The resulting mixture was plated into two 
gelatin-coated T75 flasks. 
• Aller 3-16 hours, the plates were washed well with PBS to remove 
any red blood cells or non-adherent dead cells. 
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DAY 1 Negative st~lection 
.. Prior to the negative selection, the cells were cooled at 4°C for up to 
one hour to slow the cellular processes and avoid non-specific uptake 
of bC:.lds . 
.. Anti-FcyllIlIl receptor antibody-coated beads in 3ml endothelial 
media were added to the adherent cells and incubated at 4°C for one 
houL The plates were occasionally shaken to spread the beads across 
the plate. 
e After visualizing the attachment of the magnetic heads to FcyUUH-
expressing cefls, the cells were trypsinized and resuspended in JSml 
endothelial media. 
.. The tube containing the media was placed into a magnet and the 
supernatant collected. 
.. These cells from the supernatant were plated into two gelatin-coated 
T75 plates. 
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iii) DAY 3 First positive selection 
.. As with the negative sort, the plates were first washed with PBS and 
cooled at 4DC for lip to one hour prior to positive selection. 
.. Anti-ICAM-2 antibody-coated beads in 3ml endothelial media were 
added to the adherent cells and incubated at 4 DC for one hour. 'fhe 
plates were occasionally shaken to spread the beads across the plate . 
.. After visualizing the attachment of the magnetic beads to lCAM-2-
expressing endotbeli cells, the ceJJs were trypsinized and 
resuspended in 15ml endothelial media. 
.. The tube containing the media was placed into a magnet and the 
supernatant discarded . 
.. The cells from the pellet were plated into one gelatin-coated T75 
plate. Halving the number of tissue-culture plates compensates for the 
fact that only a small percentage of the cells present prior to positive 
selection are endothelial. 
iv) DAY 5~8 Second positive selection 
.. Depending on the yield and rate of growth of endothelial cells after 
the first positive selection, a second sort was performed on day 5-8. 
Selections were optimally performed when the cell culture was 70% 
confluent. 
.. After the second positi ve sort, the culture was spl it to two or three 
gelatin-coated T75 plates, depending on the yield of tbe endothel ial 
preparation. 
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5.1.2 Results 
Depending on the success of the prcp'Jralion, once these two or three 1'75 
plates are conJluent, one can split the plates 1:3. Once these plates are 
confluent, the celIs are cryoprescrved in fetal bovine serum and 10% DMSO 
and stored at -lSO°C. Storing the cells at 500,000 cells per vial allows 
enough cells for one 10 em plate upon reptlting. 
In all, one can expect 15-20 vials of 500,000 cells following a successful 
mouse pulmonary endotbelial cell preparation using three mice. 
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5.2 CHA.RACTERIZATI()N OF PULMONARY 
ENDOTHELIAL CELLS 
5.2.1 Methods 
a) Imrnunoeytochenlistry. 
• The cells were grown to confllience in 6-well tissue culture plates, 
then the plate placed on ice. 
• After washing with PllS, the cells were fixed for 3 minutes with a 
solution of 75()/o Acetone. 2(Yk} cold distilled water, 5 of' bufTered 
formalin (10% solution). 
• The sUlnpJe was then blocked with 7°/(, rabbit serum (diluted in PBS) 
for 30 minutes at room temperature. 
• The cells were incubated overnight at 4°C with the following primary 
antibodies: 
Control: Rat IgG2A control (I~tl/ml) 
Specific: Rat anti-mouse CD31 (PECAM) OlAg/ml) 
• The llcxt morning, the wells were blocked with H::,02 (I :300 solution) 
for 10 min at room temperature. The plates were washed twice with 
PBS both before and after blocking. 
• The cells were then incubated witb rabbi t anti-rat biotinylated 
secondary antibody (2f.tg/ml) for one hour at room temperature. 
• Avidin-biotin complex, a mixture of streptavidin and biotinylated 
horse-radish peroxidase, was prepared and placed on the cells. 
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.. Colour was developed by the addition of 3,3' -diaminobenzidinc 
(DAB), vvhich produces a brown end product by the action of horse-
radish peroxidase. 
.. Haemaloxylin and Eosin Staining was then performed as follows. 
Haematoxy!in for 15 seconds. 
Hel (I ), Ethanol (7(Y?{,) solution for 15 seconds. 
N H/H-l for 15 seconds. 
.. Excess liquid was removed and the cells covered with crystal moun! 
and placed at 37°C for J hour. 
b) Immunofluorescence 
.. Wild-type and Cd39-null mouse lung endothelial cells were grown to 
70% conl1uence in normal endothelial media, then detachecl with 
trypsin (0.05%) and allowed to attach to the gelatin-coaled slides for I 
hour. 
.. Plated cells were then fixed with 4(10 parafonnaldehyde for 20 minutes 
at room temperature. 
.. Fixed cells were treated with 0.5 Triton-X for 3 minutes, then 
blocked with 5 goat serum for 20 minutes at room temperature. 
.. Slides were incubated with primary anti-o.v antibody (I :200 dilution) 
for 1 hour at room temperature. 
.. Arter washing, the secondary antibody (anti-mouse fluorescent 
ant ibocly) was applied at I :200 concentration for I hour at room 
temperature. 
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- N llclear staining was obtained using a 1 :5000 solution or Hoescht for 
5 minutes at room temperature. 
- The slides were then covered and examined under a f1uorescent 
fIlJcroscope. 
c) CD39 protein expression in wild-type and Cd39-nuH 
pulmonary endothelial cells. 
Antibodies to munne Cd39 had previollsly been developed by direct 
inoculation of Cd39 eDNA in pcDNA3 into rabbits.JR-+ We confirmed the 
expression of Cd39 protein by cultured mouse lung endothelial cells by 
Western blot analysis using this antibody. 
i) Solutions used 
-Lysis Buffer 
RIPA Buffer -- 10ml 
Aproprotinin - 50fA1 
Leupeptin -. 20~d 
PMSF 
NaFI 
DTT 
- lOO~ll of IOOmM stock solution 
- 50[d of I M stock solution 
- IO,JJ of J M stock solution 
- SDS~PAGE running buffer (lOX) 
Glycine - 143 g 
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Trizma - 30 g 
Dilute in lOOOrn] water to produce a lOX solution 
• Transfer buffer (lOX) 
'T'ris - 58.4 g 
Glycine - 29.6 g 
Dilute in lOOOml water to produce a IOX solution 
Prior to use, dilute the lOX solution in 20 l /rj methanol, 
and 70% distilled water 
• PBS/tween solution 
Phosphate hutTered sal inc (PBS) - I litre 
Tween - 500~d (['inal concentration 0.5%) 
• 5% Milk in PBS/tween 
Dry non-fat milk powder - 5g 
PBS/tween - IOml 
ii) Experimental protocol 
• Wild-type and Cd39-nul1 mouse lung endothelial cells were cultured 
to 70 confluence in normal endothel ial media. Prior to 
experimentation, the cells were starved overnight in a basal media 
containing 0.5% fetal bovine serum (FBS) and no endothelial 
mitogen. 
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• The adherent cells were collected in a 300~tl solution of Jysis buffer, 
centri rllgecl at 14000 rpm for 10 minutes, the supernatant conserved 
and the nuclear pellet discarded. 
• Sample protein concentrations were determined using the Biorad DC 
Protein Assay. 
• 30,lg aliquots were then boiled 1n SDS-PAGE Sample Buffer 
containing 2(Yr) [~-mercaptoethanol. 
• The samples were then separated hy SDS-PAGE electrophurl',sis at a 
constant voltage or 80mV in a 4-15 acrylamide gel. Constituents of 
the running buffer constituents deta iled above. 
• Protein was then transferred to PYDF membrane by Western blot at 
constant current of 75mA for 2 hours. 
• T'he membranes were then blocked in 5 milk PBS/tween solution for 
I hour. prior to probing with primary antibody (1: LOOO concentration 
rabbit anti-Cd39 antibody). 
• T'he following day, the membranes were washed, then incubated with 
1: 10 000 concentration secondary antibody for one hour. 
• Signal was then developed using the Supersignal chemiluminescent 
substrate (Pierce Biotechnology, Inc. Rockford, IL.). 
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5.2.2 Results 
Prior to using the mouse lung endothelial cells in experiments, we had to 
analyze t.he endothelial purity generated by this preparation technique. All 
experiments in this project, including the endothelial characterizations of 
this chapter, were performed using endothelial cells after 5-8 passages in 
culture. 
a) CeUular nlorphology 
Initial confirmation of a high degree of endothelial purity USlllg this 
technique came from visualization of the morphology of these cells in 
culture. Endothelial cells are descdbed as having a typical "cobble-stone" 
morphology and evidence of contact inhibition under phase-contrast 
IlIlCroscOpy. Figure 5.2.1 shows a representative example of pulmonary 
endothelial cells in culture demonstrating this classical picture. Prior to 
positive selection, the cultures contain many elongated and spindle shaped 
cells, which probably are contaminating fibroblasts. l'hese cells also grow in 
clumps because of a lack of contact inhibition. During purification these 
cells are removed and the classical endothelial morphology is seen. 
b) lmlnunocytochenlistry 
In order to rnore accurately assess the endothelia! purity of the mouse lung 
endothelial cell preparation, plated cells at passage 8 were stained with the 
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endothelial rnarker, CD31. C031, also known as PECAM-1 (Platelet 
Endothelial Cell Adhesion Molecule- J), is a member of the immunoglobulin 
superfamily that mediates cell-to-cell adhesion. It is constitutively expressed 
on the surface of adult and embryonic endothelial cells and weakly 
expressed on peripheralleukocYles and platclets. 2lS 
Even at this late passage stage, the enclothdial purity of the mouse lung 
endothelial cell preparation, as assessed by CD31 expression, was >98% 
(Figure 5.2.2 and 5.2.3). Only occasional cells fail to stain with CD3 I, 
indicating that use of cells after numerous passages is not associated with the 
overgrowth of contaminating cells. 
In order to further characterize the endothelial nature of these cells we 
stained passaged cells for von \Villebrand Factor, cty-integrin, and 13,-
integrin expression. von Willebrand Factor (v\VF) is a multirneric plasma 
glycoprotein synthesized by endothelial cells and megakaryocytes. In 
plasma, vWF functions as a carrier for Factor VIII and is a mediator of 
initial platelet adhesion to subendothelium and of platelet-platelet 
interaction. vWF is concentrated in Weibel-Palade bodies in the cytosol of 
endothelial cells/v) 
The 0. VPl integrin is thought to have a crucial role in the control of 
angiogenesis and is upregulatecl in vivo in proliferating angiogenic 
endothelium. 117 Since cultured cells also exist in an activated, proliferating 
state we decided to test the expression of (J: y r:1, by immunocytochemistry_ 
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Figure 5.2.1 - Phase contrast micros("op~' of mouse lung endothelial 
cells in cuJture, showing typical cobblestone appearance of (·uJtured 
endothelial cdJs 
Figure 5.2.2 - Antl-CD31 immunocytochemistry ~tain of cuJtured 
murine pulmonary endothelJaJ cells 
177 
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Figure 5.2.3 - Anti·{:[)Jl stainjng of cultured pulmonary 
endothelial c~Hs . 
... 
• 
Figure 5.2.4 • von Wmehrand factor l'xpression on cwtured 
pulmonary endothelial cells. 
178 
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Unlike the uniform CD31 staining that was noted on the mouse lung 
endothelial cells, only occasional cells stained for von Willebrand factor (Fig 
5.2.4). Although von Willebrand factor is normally expressed by endothelial 
celis, the loss of this factor in cultured endothelial cells followmg mUltiple 
passages is well described. 237 Also, the cultured cells failed to stain for o.v-
or f) l·integrin (data not shown) but this is probably just indicative of low 
iIltcgrin expression levels and poor sensitivity of immunohistochemical 
integrin staining. 
c) hnmunofluorescence 
As discussed in the literature review, integrin fXy133 is thought to be crucial 
for normal endothelial function during angiogenesis. Therefore, because 
standard immunohistochemistry failed to show integrin (Xvl)3 expression on 
our endothelial cell culture, we used immunofluorescence to stain 
pulmonary endothelial cells for (Xv expression. 
Figure 5.2.5 shows representative examples of fXy-integrin expression on the 
surface of wild-type and Cd39-null endothelial cells. It can be seen that the 
fly-subunit of integrin (XY~3 has preserved expression on the surface of 
cultured murine pulrnonary endothelial ce]]s. This is a further indicator of 
the endothelial nature of these cells. 
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Figure .5.2.5 - irnmunonUores('ence stajning of u,,-integrin 
~xpresshin (rl."d) Oft wild-type (Il."fl.l and CdJ9-null (tight) 
endothelial cells (upper panel). ~(-gati\'e control with onl)' 
secondary anti bOOy (Fluorescein-conugated ra bbit anti-ral IgC) 
shown below. CeJJ nudei are stained blue. 
180 
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d) Cd39 protein expression 
Although the expression of Cd39 on murine endothelium in vivo and its 
successful deletion in the Cd39-nnll mouse has been confirmed previously in 
our laboratory,lg4 we wished to confirm that Cd39 is still expressed by 
passaged wild-lype mouse lung endothelial cells. If Cd39 expressIOn IS 
down-regulated in culture in a manner analogous to the loss of vWF, it may 
compromise our future in vitro experiments. 
Antibodies to mUrine Cd39 had previously been developed by direct 
inoculation of Cd39 cDNA in pcDNA3 into rabbits.IM We confirmed the 
expression of Cd39 in cultured mouse lung endothelial cells by Western blot 
analysis using this antibody. Whole lung lysate from wild-type C57/B6 mice 
was used as a positive control. As can be seen in Fig 5.2.7, wild-type mouse 
lung endothelial cens continue to express Cd39, while Cd39 expression is 
predictably absent in Cd39-null endothelial cells. Experiments documenting 
the presence of appropriat  ATPase and ADPase activity on the surface of 
cultured microvascular endothelial cells were not repeated as this had 
previously been shown by others in the laboratory.IK4 
In conclusion, the use of this protocol for isolation of pulmonary endothelial 
cells from wild-type and Cd39-nuH mice resulted in high-purity, ex.pandable 
endothelial cultures, which continue to express a number of important 
endothelial surface proteins, including CD3] , integrin av~)' and Cd39. 
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78kDa 
Figure 5.2.7 - Western-blot analysis of Cd39 expression on wild-
type, and Cd39-null endothelial cells as well as wild-type whole lung 
lysates. Cd39 protein band is at 78 kDa. 
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5.3 ENDOTI-IELIAL PROLI}-'ERATION ASSA YS 
5.3.1 Introduction 
Resting endothelial cells have extremely low cellular turnover rates. 
However, when activated during physinlogical and pathological 
angiogenesis, endothelial cells proliferate rapidly to provide cells for the 
developing vasculature. 1 (Y/t' of endothelial cells in tumours take up BrdU or 
[11-1 I thymidi ne, indicating cellular proli fcration, as opposed to 0.2 of 
resting endothelial ceils. [59 
We have shown that Cd39-null mice have poor endothelial cell proliferation 
during liver regeneration, as opposed to wild-type animals, which show 
brisk endothelial proliferation on days 3-5 following hepatic resection. This, 
along with increased endothelial cell apoptosis in Cd39-null mice, results in 
cleCective angiogenesis and disordered liver regeneration following 70%-
hepatectomy in Cd39-nul1 mice. (Sun Xiaofeng, unpublished clata). 
Increasing evidence has emerged over the last several years, that signaling 
complexes of growth factor receptors, purinergic receptors, integrins and 
possibly Cd39, form in caveolae on the surface of endotbelial ceUs,llJ5,I'JK It is 
hypothesized that these signaling cornplexes serve to integrate signals from 
growth factors, nucleotides and the extracellular matrix to promote 
endothelial proliferation, differentiation or migration. Deletion or Cd39 
could disturb these signaling complexes in several ways. Firstly, absence of 
the Cd39 protein in caveolae on the cell surface could prevent normal 
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structural assemhly of this putative signaling complex. Secondly, absent 
ectonucleotidase activity could result in increased local nucleotide 
c()nl~entrations at the cell surface and result ill P2-receptor over-activation or 
desensitization. This might result not only in defective nucleotide signaling, 
but also could cause defects in growth factor signaling because of alterations 
in signaling complex assembly and function. P2-receptor desensitization 
involves, as with other G-protcin coupled receptors, phosphorylation of the 
receptor by a protein kinase, or uncoupling of the receptor from its 
associated G-protcin. l77 This phusphorylation or uncoupling may affect 
targeting of P2-receptors to signaling complexes and, hence, signaling 
complex function. 
During angiogenesis, endothelial cells come into contact wi th different 
extracellular matrix proteins, which provide important signals to these 
proliferating, migrating endothelial cells. 85 It is possible that different 
integrins, binding different matrix substrates, could co-localize in these 
putative signaling complexes and result in differing effects in vivo and ill 
vitro depending 011 which matrix component the cell is bound. 
For exarnple, the integrin uvI3], which binds RGD-sequences on both 
vitronectin and fibronectin, has been shown to associate with the purinergic 
receptor P2Y 2' providing a possible link between nucleotide signaling and 
integrin function. 195 Deletioll of Cd 3 <) may thus inhibit endothelial cell 
proliferation on some, but not all, basement membrane substrates. 
Because or these putative 1 inks between growth factor receptors, integrins 
and nucleotide-mediated signaling, we measured the in vitro proliferation of 
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wild-type and Cd39-null endothclial cells, firstly, in response to varIOUS 
gmwth factors, and, secondly, on a numher of different extraceUular matrix 
substrates. 
5.3.2 Methods 
a) BrdU uptake proliferation assay 
• 96-we11 plates were coated overnight at 3rC with gclatin (J ~tg/ml), 
vitronectin (3~tg/ml) or fibrollcction (40~g/ml). Prior 10 lise, the \vells 
were washed once with PBS. 
• Wild·-type and Cd39-null endothelial cells were cultured to 70%-
confluence, then trypsinized, seeded at 10000 cells/well in the matrix-
coated 96-well plates and starved overnight in basal endothelial media 
containing O.5 IYr, FBS. 
• The following morning, the cells were stimulated with control media 
containing 20 r':"BS, or control media (20% FBS) plus insulin 
(IOnM), vascular endothelial growth factor (VEGF, lOng/ml), 
hepatocyte growth factor (HGF, SOng/ml), fibrobJast growth factor 
(FGF, IOng/rnl), or insulin-like growth factor I (lGF-l, IOng/ml). 
,. Arter 24 hours. the proliferating cells were pulsed with BrdU (HhtM) 
for g hours. 
,. BrdU uptake was measured using the BrdU Labeling and Detection 
Kit III (Roche Diagnostics Corp. Indianapolis, IN) 
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incorporated BrdU. 
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b) [3H] thymidine uptake proliferation 
.. experiment was IJ1 same manner as the B 
assay, that, after hour incubation with 
were pulsed 8 hours WJ Iwell 
(Amersham Pharmacia B , Piscataway, 
.. After 8 the plates were washed in and for 
15 in 10% trichloroaceLic 
.. The cells were with and 200!!l NaOH was 
added to 
.. llation and analyzed the 
Liquid 
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5.3.3 Results 
a) Assessment of endothelial cell proliferation by 
incorporation of UrdU 
"l'he BrdU assay works on the principle that 5-bromo-2-deoxyuridine (BrdU) 
is a thymidine analogue, which partially replaces thymidine during the 
process of DNA synthesis. Following partial denaturation of double stranded 
DNA, this BrdU is detecled using a peroxidase-conjugated anti-BrdU 
antibody. 'rile development of a green colour following addition of 
peroxidase substrate is then measured on a mjcroplatc reader.I()o 
Incorporation of RrelU occurs during the S-phase or the cellular growth cycle 
and is, thus, a measure of in vitro cellular prolil'eration. 
When plated on gelatin, wild-type and Cd39-null endothelial cells had equaJ 
BrelL! incorporation in the 20% serum control group and in response to 20<7r; 
serum plus IOng/ml YEOF, JOnM insulin, lOng/ml 10F-l, SOng/ml HGF, or 
IOng/ml FGF. Each of these growth factor~ failed to demonstrate in vitro the 
defective proliferation of Cd39-nuIl endothelial cells, which had been noted 
in vivo. (Figure 5,3, I, Table 5.3.1). 
Unfortunately, the growth factors failed 10 induce increased proliferation 
over the baseline control in either wild-type or Cd39-nuJl endothelial cells. 1t 
has previously been shown that YEGF, in particular, can induce endothelial 
proliferation in vitro. In a study using prj mary hepatic sinusoidal endothelial 
cells, VE~(H~ was shown to promote a 7'YYc increase in proliferation over 
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baseline?l~ Unfortunately, in this study, the serum concentration used at 
baseline was not published making comparisons with our resuhs difficult. 
[11 various other studies using different endothelial cell populations, PGF, 
insulin, IGF-l and HGF were each shown to promote endothelial 
pmlifcration to varying degrees, !,'!,2 [() 
The lack of growth factor effects in this experiment can be explained by the 
high serum concentration used. Our carlier experiments using either no 
serum or low serum concentrations ((L5 FBS) resulted in no proliferation 
in either the wild-type or Cd39-null endothelial cells in b th the control and 
growth factor-stimulated groups. (ShaLlil Jackson, unpublished results) The 
mouse lung endothelial cells lIsed in our experiments are exquisitely 
sensitive to removal of serum and become apoptotie within hours. (Shaun 
Jackson, unpublished results). For this reason, we decided to use 20 l j{) FBS 
for the remajnder of our proliferation assays. 
Although, this results in the absence of significant increases in endothelial 
cell proliferation following growth factor stimulation, we are still able to 
compare the proliferation rates of wild-type and CdJ9-null endothelial cells. 
T'he consistent feature in this experiment is that there is no decrease in Cd39-
null endotheli~d eel1 proliferation in vitro compared with wild-type cells. 
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b) Assessment of endothelial ceB proliferation by 
incorporation of 3H-thyrnidine 
In the thymidine incorporation assay, 13 H] Thymidine is incorporaled into 
the newly synthesized DNA of proliferating cells. Subsequent quantification 
of' jlHJ thymidine is then performed by scintillation counting of 
autoradiography. The measurement of BrdU incorporation by proliferating 
cells is often llsed in proliferation assays instead of 3H-lhymidine, because 
this avoids the use of potentially dangerous radioactive isotopes. fJowever, 
the assessment of cellular proliferation has been shown to be equal using 
either method. 241 
We decided to confirm our BrdU uptake results by meaSUrIng the 
proliferation of wild-type and Cd39-·nuJJ endothelial cells by1H-thymidine 
incorporation. (Figure 5.3 Table 5.3.2) As expected, the proliferation or 
wlld-type and Cd39-null endothelial cells was egualin the 2fVYc) FBS control 
group (wild-type IOO±39.2°;() vs. Cd39-null 97±44.1 %. P=0,47). The 
proliferation of wild-type and Cd39-null endothelial cells was <llso equal in 
the VEGF-stimulated grou p (wiIJ-type I 35± 19.4(fr) VS. Cd 3 9-n u 11 
I J3.4±36.6%. P=0.47). 
lnlerestingly, in this experiment, there was a trend towards Iflcreased 
proliferation in the VEGF-treated groups. This is consistent with robust 
VEGF-indnced activation of ERK I 12 in wild-type and Cd39-null endotheli;:.il 
cells (vide infra, Chapter 5,4). However, the increase in proliferation was not 
signilicant in either the wild-type (P= 0.12) or Cd39-null (P=O.17) groups. 
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'['he most likely explanation for the disparity between growth factor 
activation and cellular proliferation, is that phosphorylation of ERKl/2 is a 
more sensitive index of VEGF activity than proliferation, which IS 
dependant on a number of other factors. including serum concentration. 
The consistent feature, however, is that there is no decrease in the in vitro 
proli I'eration of Cd39-nnll endothelial cells compared with wi ld-type cells 
when plated onto gelatin. 
c) Endothelial ceH proliferation on different extracellular 
matrix conlponents 
Although we showed no difference in the proliferation of wild-type and 
Cd39-null endothelial cells on gelatin, we have hypothesized that Cd39-null 
cells might have poor proliferation on fibronectin or vitronectin because the 
integrin nVr)3 associates with purinergic receptors in cell-membrane 
signaling complexes. UVr:)3 binds ROD-sequences on a number of 
extracellular matrix components, including fibronectin and vitronectin. 
However, we showed no difference between the proliferation of wild-type 
and Cd39-null endothelial cells on either fibronectin and vitronectin (Figure 
5.3.3, Table 5.3.3). There was equal BrdU uptake in wild-type and Cd39-
null endothelial cells plated on fibronectin (wild-type 116.2%± 11.6% vs. 
Cd39-null 123.5± 14.3%, P=O.26) and on vitronectin (wild-type 33.4± 17,9% 
vs. Cd39-nuJ1 37 8.5. P=O.36). In keeping with previous results, the 
BrdU uptake of wild-type and cells Cd39-null plated on gelatin was also 
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Tahle 5.3.1: F~ndothelial cell BrdU uptake in wild-type and Cd39-null 
endothelial cells stimulated with various endothelial growth factors. 
Experiment performed on 96-well plates pre·-coated with gelatin (I ~lg/ml). 
Results expressed as a percentage of wild-type control BrclU uptake ± 
standard deviation. 
- ·····-·--·····T-··--·-··--·,~·--·----·~·--;-···--·--·-~······-····-T··-·---····--··-~-,---··-·-·-···--,--··· .......... _--.. - ... , 
Control VEGF IGF-I HGF 
(lOng/mI) (50ng/mi) 
....... ~--~ ... --... -j--.. -.--.-.--... -.:-.-- .. - ... --.. ~~····----1 
Wild-type I 96.4.-+: 11.5';;' 
Cd39-nuH I OUl)!: 13.3% 89 .. h 15.6'16 
Tabie 5.3.2: Endothelial cell JH-thymidine uptake in wild-type and Cd39-
null endothelial cells stimulated with control (20(Yr) FBS) or VEGF (JOng/ml 
plus 20% FBS). Experiment performed on gelatin-coated 96-well plates. 
Results expressed as a percentage of the wi lei-type control group ± standard 
deviation. 
Control VEGF (lOng/mI) 
'VHd-type 100±39.2% 135±19.4% 
... -. 
Cd39-nuH 97±44.1% 133.4±36.6l ){. 
, .........•. 
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Table 5.3.3: Endothelial cell Brei U uptake in wild-type and Cd39-nu II 
endothelial cells stimulated with 20(/rJ FBS on 96-well plates pre-coated with 
gelatin (I ~g/ml), fibronection (40~g/ml), or vitronectin (3fAg/ml). Results 
expressed as a percentage of wild-type control BrdU uptake (gelatin sample) 
± stanciard deviation. 
Wild-type 
Cd39-nuH 
Gelatin 
lOO± 18.9% 
114.9± J 8.6(Yr) 
Fibronectin 
116.2± J 1.6% 
.5± 14.3% 
Vitronectin 
33.4± 17,9% 
.Yk: 
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.. pt'rCt'utat.!~ of wi!d-t,\pe ('nntrui Hrdl uptakt'. Bar ... 111mw ml'an 
cdlular BnH r upl<lkl' ± s.Ld. 
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5.4 ACTIVATION OF' ENDOTIIELIAL ERKl/2 
(p42/44-MAPK) BY VEGI~~ 
5.4.1 Introduction 
196 
\Ve have hypothesized that there is a defect in growth factor signaling in 
Cd39-null endothelial cells in that deletion of Cd39 results in disruption of 
growth factor signa] ing complexes. Althougb we failed to show a difference 
in the proliferation of wild-type and Cd39-null endothelial eel Is in response 
to YEGF, the high serum concentrations required in this experimental model 
prevented us from concluding that no defect exists in Lhe intracellular 
signaling of individual growth factors. 
We chose to study the intracellular signaling cascades of VEGF. in 
particular, because VEGF is the most potent angiogenic protein known. 54 
VEGF promotes angiogenesis by increasing vascular permeability,5() by 
stimulating endothelia proliferation and by protecting newly-formed vessels 
from regression by acting as an endothelial survival factor. 57 VEGF mediates 
several of these actions by the activation of mitogen activated protein 
kinases (MAPKs), in particular p42/44-M APK (also known as extracellular 
signal-regulated kinase 112 (ERK 1/2)).51 Activation of ERK 112 protects 
endothelial cells from apoptosis and promotes proliferation by promoting 
entry into the cell cycle?f2 
Because of the importance of VEG induced activation of endothelial 
ERKlI2 in angiogenesis, we measure this activation in wild-type and Cd39-
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null endothelial cells. ERK 112 activation was assessed by Western blot 
analysis Llsing a phosphospecific antibody recognizing Threonine 
202/Tyrosine 204 phospborylation of ER K 1/2 (Cell Signaling Technology, 
Inc. Danvers, MA). 
5.401 l\rlethods 
• Wild-type and Cd39-l1ulJ mouse lung endothelial cells were cultured 
to 70 confluence in normal endothelial media. Prior to 
experimentation, the cells were starved overnight in a basal media 
containing 0.5% fetal bovine serum (FBS) and no endothelial 
mitogen. 
• The cells were then stimulated for 5 minutes with media containing 
VEGF (I Ong/ml) or control media without growth factors or serum. 
• Western blot analysis was performed as described ill 5.2.1 (c), using 
anti-phospho-ERK 1I2 (Thr202, Tyr204) as the primary antibody. 
• After development, the membranes were stripped using Restore 
Stripping B urfer (Pierce Biotechnology, Inc. Rockford, fL.) and 
reprobed with antibodies to unphosphorylatecJ ERK lI2 to correct for 
differences in protein loading for each sample. 
• Unphosphorylated ERK 1 levels were then measured as above. 
• Results are expressed as the ratio of phosphorylated ERKl/2 to total 
ERK 1/2. Results are the average of three independent experiments ± 
standard deviation. 
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5.4.2 Results 
VEGF induced rapid and equal phosphorylation of ERK1I2 111 wild-lype and 
Cd39-nul1 endothelial cells at 5 minutes (wild-type I ()(h6.8 vs Cd39-null 
99.7%±6.6%. P=O.48. Figure 5.4. I. Table 5.4.1.). This implies t.hat deletion 
of Cd39 does not result in defective VEGF-signaling. One could argue that 
without prior stimulation with nucleotides, the P2-receptor desensitization 
that we have hypothesized would disrupt signaling complexes on the surr~lCe 
of endothelial cells would not have occurred. However, we have shown 
defective Cd39-null endothelial cell adhesion and intcgrin signaling in the 
absence or nucleotide pre-treatment (results shown in chapters 5.8 and 5.9). 
Because pre-treatment with soJubleNTPDase corrected these defects, we 
have concluded that certain P2-receptors on Cd39-null endothelial cells are 
desensitized at baseline in culture -- probably because of local paracrme 
nucleotide release by endothelial cells. 
I nteres tingly, the unsti mulated ERK 112 activation state of wild-type 
endotheljal cells was significantly greater than that or Cd39-null endothelial 
cells (wild-type J8.2±2.1 vs Cd39-null 6.2(1£:J±2.0%. P=O.OO I). Thus, even 
at the baseline state in culture. there is a djfference in the activation oC state 
of the important signaling molecule ERK I 12. However, this difference was 
not seen following VEGF stimulation leading us to feel confident in 
~ ~ 
concluding that no defect in VEGF signaling exists in Cd39-null endothelial 
cells in vitro. 
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Tahle 5.4.1: Relati ve phosphorylation of ERK 112 following stimulation of 
wild-type and Cd39-null endothelial cells for 5 minutes. Relative ERK J 12 
phosphorylation is expressed as the intensity of the phosphorylated ERK1I2 
divided by the total ERKl/2. Results are expressed as a percentage of 
maximal phosphory lmioll ± standard deviation. 
\Vild-type 
Cd39~nun 
Figure 5.4.1 
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Ii'igure 5.4.1 - Phosphorylation of ERK1I2 in wild-type and Cd39-null 
endothelial cells following stimulation with VEGF for 5 minutes. Reslilts 
shown are a ratio between phosphory lated and un phosphorylated (tota]) 
ERK I 12 for each experimental condition. Results are expressed as a 
percentage or wild-type VEGF-stimulated ERK 112 phospbory laUon. Bars 
show mean ERK l!2 pl1ospilorylation ± s.Ld. 
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5.5 END()THELIAL APOPTOSIS ASSAYS 
5.5.1 Introduction 
The balance between endothelial cell survival and apoptosis has been shown 
to playa major role in the development of tumour vasculature. In order to 
promote angiogenesis, tumour cells frequently secrete endothelial cell 
survival factors sllch as VEGF. Immature blood vessels seem particularly 
prone to endothelial cell apoptosis and vessel regression following the 
inhibition of this tumour-derived VEGF.'6 
In addition. tumours transplanted into mice deficient in the pro-apoptotic 
molecules Bax or acid sphingo-myelinase were more resistant to 
radiotherapy and contained a lower incidence of endothelial cell apoptosis 
than the same tumours transplanted into wild-type animals. 243 
Therefore, the inhibition of endothelial survival factors or the activation of 
endothelial cell apoptosis is an attractive anti-tumour strategy.2~A [n fact, 
several anti-angiogenic therapies currently undergoing clinical trials seem to 
exert at least part of their anti-tumour action by promoting endothelial cell 
apoplOsis, including ncovastat,245 anginstatin47 and endoslatin.2-+6 
Purine signaling has an Important role to play in altering this balance 
between cellular survival and apoplosis in a number of important 
physiological and pathologic~t1 settings. For example, the turnover of 
keratinocytes in tbe stratified squamous epithelium of the skin is controlled 
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5.5.21\1Iethods 
a) Staining apoptotk cells using ApopTag® Peroxidase Kit 
.. Wild-type and Cd39-null endothelial cells were grown to 70 
confluence in 6-well tissue culture plates, then treated with 200~lM or 
2mM ATP fOor 4 hours. 
• Apoptosis induction was assessed by staining the plated cells with the 
ApopT'ag® Peroxidase Kit (CHEMICON International. 'femecula, 
CA) 
• The plated cells were fixed in 1(10 paraformaldehydc in PBS, pH 7.4 
for 10 minutes at room temperature. 
.. Arter three washes with cold PBS, the endogenous peroxidase was 
quenched in 3 H~02 in PBS for 5 minutes. 
.. After three more washes with cold PBS, equ ilibration buffer 
(ApopTag® Peroxidase Kit, CHEMICON) was placed on the cells for 
at least 10 seconds, and then working strength TdT enzyme 
(ApopTag@ Peroxidase Kit, CHEM[CON) was incubated on the cells 
for 1 hOllr at 37°C. 
.. After washing, anti-digoxigenin peroxidase conjugate (ApopTag@ 
Peroxidase Kit, CHEMICON) was applied for 30 minutes at room 
temperature and the colour was developed by staining with peroxidase 
substrate (i\popTag@ Peroxidase Kit, CHEMICON). 
.. Plates 'vvere then counterstained in 0.5 methyl green and covered. 
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.. Positively stained apoptotic cells were then counted under the 
microscope and results expressed as the average number of cells 
stained per high-power field in three separate tissue culture wells. 
b) Measurement of endothelial apoptosis by flow cytometry 
.. Wild-type and Cd39-null endothelial celIs were treated with 
staurosponne 200nM or a range or concentrations of A'T'P, and 
Adenosine for 16 hours. 
.. Both adherent and floating cells were then harvested, washed twice 
with cold PBS and fixed overnight in 100% ethanol at -20"C. After 
fixation, the cells were again washed twice in cold PBS before being 
stained in propidium iodide butTer for onc hour at room temperaturc. 
.. The propidium iodide bu ller consisted of 0.1 TritonX-lOO, 0.1 mM 
EDTA (p~-f 7.4), 0.05 mg/ml RNAse A (50 U/mg) and 50 f.tg/rn] 
propitlium iodide in phosphate buffered saline (pH 7.4). 
.. DNA staining of permeabilized cell stained with propidium iodide 
was then performed hy fluorescence-actjvated cell sorter (FACS) 
analysis with excitation at 488nrn (blue) and detection at 620nm (red). 
5.5.3 Results 
a) Staining apoptotic cells using ApopTag® Peroxidase Kit 
lnduction of apoptosis results in the activation of a nuclease, which cuts 
genomic DNA between nllcleosomes and generates DNA fragments with 
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lengths corresponding to multiples of 180 base pairs. 'rhis results in the 
generation or multiple free 3' -OH DNA termini, which are absent in normal 
and proliferative nuclei?fX The reagents provided in the ApopTag@ 
Peroxidase Kit (CHEMICON International, Temecula, CA) are designed to 
label these free 3'--OH DNA termini in situ with digoxigenin-labeJed 
l1ucleotides using the enzyme terminal deoxynucleotidyl transferase (TdT). 
An anti-digoxigenin antibody is then allowed to bind to the digoxigenin-
conjugated nucleotide oligomer. The peroxidase reporter rllolecule 
conjugated to lhe antibody generates an intense localized stain ['rom 
chromogenic substrates, allowing the detection of apoptotic cells. 249 
We compared the induction of apoptosis in plated wild-type and Cd39-null 
endothelial cells following 4 hours of treatment with ATP at concentrations 
of 200IJ.M and 2mM. Apoptotic cells where then stained with the ApopTag@ 
Peroxidase Kit and apoptotic cells counted manually. Apoptosis is reported 
as the average number of apoptoLic cells per high-power field with three 
wells of a 6-well plate per condition. 
Figure 5.5.1 and table 5.5.1 show apoptosis induction rates for wild-type and 
Cd39-null endothelial cells folJowing treatment with 200~lM and 2mM A"fP. 
As expected from previous studies, higher concentrations of A'fP induced 
increased apoptosis in both wi lei-type and C d3 9-null endothe!lal cells. 
However, there was no significant difference in apoptosis induction between 
wild-type and Cd39-null cells at either 200~tM ATP (P::::O. i5) or at 2mM 
ATP (P=O.13). 
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Although a trend towards increased apoptosis in Cd39-nuU endothel ia! cells 
is observed at the higher ATP concentration, counting of apoptotic cells is 
both tediolls and prone to wide ranges of error. For this reason, we cannot 
conclude that Cd39-11UIl endothelial cells are more prone 10 apoptosis 
following treatment with ATP. In order to increase the accuracy of our 
assessment of apoptosis induction, we decided to measure DNA 
fragmentation by flow cytometry. 
b) l\leasurement of endothelial apoptosis by flow cytometry 
An alternate method for assessing DNA fragmentation in apoptotic nuclei is 
the measurement by flow cytometry of the percentage of nuclei with 
hypodiploid content,2S0 This is performed by staining nuclear DNA 'vvith 
propidium iodide, a dye that binLls the DNA helix and Ouoresces strongly 
red. Because propjdiurn iodide also stains double-stranded RNA, this is 
removed by the prior addition of ribonuclease A (RNAse A). 
Following staining of permeabilized cells with propidium iodide and FACS 
analysis, the normal stages of the cell cycle are denoted by the major diploid 
peak (Go/G I phase), a hyperd iploid region (S phase) and a tetraploid peak 
(G/M phase). The region below the GjG
1 
peak is designated An and is 
indicative of cells undergoing apoptosis-associated DNA degradation. 
(Figure 5.5.2). 
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Table 5.5.1 Number or apoptotic cells per high-power field following 
staining of apoptotic nuclei (± standard deviation) 
ATP Control 
Concentration 
Wild-Type 0.3 ± 0.6 
~-
Cd39-nuH ± OJ) 
I>-values 
I 
I 
Figure 5.5.1: 
Control 200mM 
ATP 
200[!M 
l.5 ± 1.1 
9 ± 0.8 
0.15 
2mM 
2mM 
5.6 ± 3.1 
13.6±7. 2 
0.13 
: rJ Wild-type 
i" CJ:-El-rlull 
Figure 5.5.1 - ATP induction of apoptosis in wild-type and Cd39-null 
endothelial cells by immunohistochemical staining of apoptotic cells using 
the Apop'I'ag@ peroxidase kit. Results are expressed as the number of 
apoptotic cells per high-powered field ± s.Ld. 
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For flow cytometry analysis, wild-type and Cd39-null endothelial cells were 
grown to confluence and then treated with varying concentrations of ATP 
and adenosine for 16 hours. Staurosporine (200nmolll) was used as a 
positive apoplotic control. Staurosporine, derived from the bacterium 
Streptomyces staurosporcus, is a relatively non-selective protein kinase 
inhibitor, which is often used experirnentally to induce apoptosis. 251 After 
induction of apoptosis, both adherent and floating cells were harvested, 
permeabilized and stained with propidiulll iodide. The cells were analyzed 
by flow cytometry and the region below the Go/G 1 peak gated. Apoptosis 
induction results are expressed as the percentage of the total cell population 
that is gated and are an average of three indepcndent experiments. 
This protocol provides a far more accurate metbod of determining apoptosis 
induction than can be achieved by manually counting cells stained using thc 
ApopTag@ kit. Annexin V staining is a very sensitive index of cellular 
plasma membrane pertubation and was not used. We did, however, 
determine the induction oC apoptosis in wild-type and Cd39-null endothelial 
cells following treatment with ATP or adenosine by cytofluorometric 
analysis using propidium iodine. We added adenosine because we wished to 
determine whetllcr differences in apoptosis induction between wild-type and 
Cd39-lwll endotheHal cells occurred because of differences in AT'P 
concentrations at the cell surface or because of altered adenosine generation. 
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In addition, we decided to lise lower AI'P concentrations for the FACS 
experiments than was used in the ApopTag® experiments. Instead of using 
200f1M and 2mM ATP, we used lOO~tM and 1 mM ATP. The reasons for this 
decision were: firstly. that these concentrations of ATP wOLtId bctter reflect 
the nucleotide concentrations to which endothelial cells are exposed 
physiologicalJy;l~() and, secondly, that using high concentrations ATP 
solutions in vitro could expose the endothelial cells to addhional stresses 
unrelated to nucleotide signaling. For example, preparation of a IOOmM 
Arp stock sol ution requires the addition of 170mM NaOH solution to 
correct to pH to 7.4. Therefore, the addition of high concentrations of ATP 
would alter the Na+ concentration of the culture media and may also alter the 
pH because of hmitations in the accuracy of our pH correction. 
Figure 5.5.3 and Table 5.5.2 show apoptosis induction of wild-type and 
Cd39-null endothelial ce]]s following treatment with I OO~lNI and 1 mM ATP. 
Figure 5.5.4 and Table 5.5.3 show corresponding results for lOO!-AM and 
J mM adenosine treatment. 
As can be seen from these results, both wild-type and Cd39-null cells 
showed minimal induction of apoptosis by either ATP or adenosine 
treatment. The reasons for th1s are not readily apparent hecause previous 
studies in our laboratory have shown apoptosis induction of 9.6(li') and 16.1 
foJJowing treatment of human umbilical vein endotheLial cells (HUVECs) 
with 1 OO~,tM and 1 mM ATP, respectivcly.252 Adenosine was not used to 
induce endothelial apoptosis in this project. 
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It is possible that the different source of endothelial cens used in these 
previolls experirnents account for the observed differences in results 
obtained. Prirnary pulmonary endothelial cells may be more resistant to 
apoptosis than commercial HUVEC ce1llines. Indeed, 200nM staurosporine 
induced 69.24% apoptosis in H UVECs but induced only halJ the amount of 
apoptosis in our pulmonary endotbelial celIs. 
In our experiments, I mM ATP induced signi "icantly greater apoptosis ill 
('d39-null endothelial cells than wild-type cells (wild-type I ± OJ)(df) vs, 
Cd39-null J.7 ± 0.1 . P=O.OO I). Although statistically significant, these 
resliits are not clinicaJly significant as induction of less than 2 apoptosis 
could not explain the angiogenesis defect observed in Cd39-null animals. 
Similarly, although there was also statistically signif'icant increases in 
apoptosis Induction in Cd39-null cells following l()O~lM and ImM 
adenosine treatment (p=O.005 and OJ)04, respectively), the level of apoptosis 
induction would almost certainly not have a significant effect in vivo. 
An interesting explanation for this finding could be that C57BL/6 mice are 
relatively more resistant to the cytotoxic effects of higtl-dose ATP because 
of a naturally occllrring mutation in the P2X 7 receptor.
25l Adriouch et aL 
have reported an allelic mutation (P451 L) in the cytoplasmic tail or P2X/ in 
a number of commonly used mice, including C57BL/6 (but 110t BALB/c). 
This mutation n:~sults in significantly decreased ATP-inducedP2X7 pore 
formation.25J 'This is consistent with previous work showing that transfected 
murine P2X/ is less sensitive to ATP than the rat or human counterpaIi.254.255 
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As all of our in vitro experiments use endothel ial cells derived frorn 
C57BLl6 mice, it is possible that the lack of demonstrated apoptosis occurs 
independent of Cd39 ectonucleotidase function -- an attractive hypothesis 
given the signiCieant effect of ATP on human umbilical vein endothelial 
eel Is using the same experimental methodology. It would be interesting to 
repe,lt these experiments on a BALB/e background, but unfortunately, we 
have bt~en unable to successfully breed BAL13/c Cd39-null mice to date, 
perhaps because of this backgrounds increased sensitivitiy to ATP. 
l-lowever, given these in vitro findings, we can be relatively confident in 
concluding that the observed increase in endothelial ceU apoptosis in Cd39-
null animals during liver regeneration is not explained by altered induction 
of endothelial apopLosis by extracellular ATP or adenosine. Alternate 
mechanisms, for exampJe changes in vascular integrin function, may be 
responsible for this finding. 
Finally, it is interesting to note that our positive control, staurosporine, 
induced significantly greater apoptosis in wild-type endothelial cells than 
Cd39-null cells (wild-type 36.4 ± 4.4(/0 vs. Cd39-nul1 25.5 ± 5.2. P=O.024). 
('d39-null mice have an increased incidence of spontaneous malignancy, in 
particular liver tumours and lymphoproliferative malignancies, later in life 
(Sun Xiaofeng, unpublished observation). Of course, we have not fonnally 
studied the induction of apoptosis in hepatocytes or lymphoid cens, but it is 
intruiging to postulate that this increased tumour formation is due, in part, to 
decreased cellular apoprosis in Cd39-nuJJ tissues. 
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analysis (± standard deviation) 
p 
Table :Percentage apoptotic 
FACS analysis (± standard deviation) 
Adenosine 
212 
ls follD\ving ATP treatment by FACS 
ImIVI 
36 ± 4.4 
1.7±O,] 
0.001 0.02 
Is lowi treatment by 
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5.6 MATRIX METALL()PR()TEINASE 
EXPRESSION 
5.6.1 Introduction 
216 
The matrix rnetalloproteinase system has been shown to be crucially 
important in the control of angiogenesis. W),93 Matrix metal1oproteinases are 
responsihle for the digestion or extracellular matrix by migrating endothelial 
cells during the sprouting phase of angiogenesis. This is demonstrated by the 
use of natural and synthetic MMP inhibitors to inhibit angiogenesis, and by 
the finding that deletion oflVllVlP-2 and MlVIP-9 in mouse models results in 
poor physiological and pathological angiogencsis. X'lYU()7 
However, excessIve digestion of" connective tissue can have detrimental 
consequences. For example, cardiac rupture following acute myocardial 
infarction has bccr~ cited as a complication of inflammatory cells-mediated 
digestion or the infarcted myocardium. In a murine model of myocardial 
infarction, deletion of urokinase-type plasminogen activator (u-PA) or 
gelati nase 15 (lVI iYIP-9) protected Tn ice against myocard ia 1 rupture, a 
complication that affected 3WYr! of the wild-type mice. However, the lack of 
matrix digestion in theses mice also limited angiogenesis and myocardial 
remodeling, and predisposed these mice to cardiac arrhythmias and to 
cardiac failure. Interestingly, administration of plasminogen activator 
inhihitor-I (PAl-I) or a MMP inhibitor (T'IMP-l) protected wi Id-type mice 
against rupture without affecting inrarct remodeling, and. as such, may prove 
an erfecti ve therapy to prevent rupture ft)lIowing myocardial infarction. 'o, 
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Of relevance to the field of purinergic angiogenesis, is the observation that 
Cd39-·null mice are also protected from cardiac rupture following the 
induction of myocardial infarction. However, like the u-PA-/- ~md MMP-9-/-
mice. ttlese mice demonstrate poor infiltration or inflammatory cells and 
defective angiogenesis in the infarcted tisslle. This prevents e ecLive 
remodeling of the myocardium and causes the Cd39-null mice to die of 
cardiac failure in the weeks following the infarction. 
The expression of matrix metalloproteil1Llses in the infarcted tissue of Cd31)-
null mice is significantly decreased compared with infarcts in wild-type 
mice (JVlika Ogawa, unpublished results). While this offers a probable 
explanation for the absence of cardiac rupture ll1 Cd39-null mice, it does not 
answer whether this occurs because of decreased production of MMPs by 
Cd39-nuJI intlaJllmatory and endothelial cells, or whether the lack of MMPs 
is merely the result of defective invasion ofMMP-producing cens. It is quile 
possible that ~my angiogenesis inhibitor could prevent cardiac rupture 
following acute myocardial infarction by blocking the migration and action 
of those cells which digest and weaken the infarct. 
For this reason, we decided to measure the pnxiuction of MMPs by wild-
type and Cd39-null endothelial cells in vitro. It has previously been shown 
that endothelial ce1ls release vesicles that contain Ml\1P-2 and MMP-9. By a 
process or ultracentril"ugatiol1 we were able to purify these endothelial 
vesicJes and measure their metalloproleinase expression by enzyme 
/',ymography.25h 
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5.6.2 Methods 
.. Wild-type and Cd39-null endothelial cells were grown to 70 
conrluence in 6-well plates. Prior to plating, cel1s were counted to 
ensure an equal number of cells in each well. 
.. The experimental groups were: 
- Control- normal endothelial media plus O.SLio serum 
- VEGF - HJng/ml VEGr: plus endothelial media with O.YJ(J serum 
.. For the culture media MMP expression experiments, 500~d of media 
was incubated with each well for 48 hours. 
.. For the vesicle purification experiments, 500!l1 of media was 
incubated in each well for <) hours. 
.. In the vesicle purification experiments, media (S()(htl) was collected 
and centrifuged at 600g for 15 minutes, and then the supernatant 
centrifuged at 1500g for 15 minutes, in order to remove any lloating 
ceUs or debris. 
.. The supernatant was then centrifuged at IOO,OOOg for I hour at 4°C in 
order to pellet the secreted endothelial vesicles. 
.. The pellet was then dissolved in 80~d PBS and stored at -8()OC until 
analysis by zymography. 
.. For zymography, 7.Yf() SDS-·PAGE gels containing lmg/m! gelatin 
type 13 were prepared. The samples (eitller endothelial media, or 
puril"ied vesicles) were then diluted in SOS-PAGE sample buffer 
(20~.t1 4x buffer) in non-reducing conditions without heating, and 4SpJ 
of sarnple/SDS-PAGE sample buller separated by electrophoresis. 
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.. The gels were then washed in 2.5% Triton X-IOO for 60 minutes at 
roOin temperature. 
.. The gels were incubated overnight at 37°C in collagenase buffer 
containing 50mmolll Tris-HCI, lOmmol/l CaC1 2• and 150mmol/1 
NaCl. 
.. The gels were stained for I hour in Coomassie Blue in a 4: 1:5 mixture 
of methanol, acetic acid and water. 
.. The gt~ls were then destained in the same 4: 1:5 mixture of methanol, 
acetic acid and water. 
.. Matrix metaUoproteinase activity was visualized as distinct clear 
bands, indicating hydrolysis of the gelatin substrate in the gel. 
.. Prior to performing the experiment, zymography was performed on 
samples of normal endothelial media plus varying concentrations of 
serum, to control for the presence of matrix metalloproteinases in fetal 
bovine serum (FBS). 
.. The amount of geJatin digestion was quantified by jnvertjng the image 
and then measuring the band intensity by densitometry. 
.. Experiments were repeated in triplicate. 
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5.6.3 RESULTS 
Serum is known to contain matrix metalloproteinases, but is also needed for 
endothe I ial cell survi val. Primary mouse lung endotbel ial cells arc 
particularly sensitize to total absence of serum and become apoptotic within 
a few hours. Therefore, we had to determine what concentration of serum 
would allow endothelial survival without confounding our experiment by 
introducing exogenous proteases. 
We separated fresh endothel ial media contain ing varying concentrations of 
fetal bovine serum (FBS) in a SOS-PAGE gel containing I mg/ml gelatin. 
After incubation in collagenase buffer, we stained the geJ in coomassie blue 
and measure the clear bands uf gelatin digestion. Figmc 5.6.1 shows a 
representati ve example of a gel digested by the varying concentrations of 
fetal bovine serum. Figure 5.6.2 is a graphical representation of serum 
rnetalloproteinase activity in this experiment. 
l~'rom this we can confirm that there is negligible MMP-2 or MMP-9 in the 
endothelial media if 1 % FBS or less is used. Therefore, for the remainder of 
t.he experiments we used O.Y,k) FBS, liS experience had shown that this 
concentration of serum was sufficient for l110uselung endothelia] cell 
survival. 
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Figure 5.6.1 J\lt'a.'ourement of the endogenous malrix-
metalloproteinase adhit)' of fHal bovine serum (FRS) bJ; 
zyrnography. Clear bands represent areas of' gelatin dig('stion and 
correspond to matrix-metalloproteinase 2 (M.J\lP-2) and matrix-
metalloprotein~ls('-9 CMMP-9). 
J 2(1 
1(0 
MMP-9 
M::\W-2 
Ct~t,'P-" 
.M,..,F'·9 
(0 I Cl..... 
Percentage FBS 
Figure 5.6.2 - Graphical represenlalion of the endogenous matdx-
metalloproteinase acth'ity of (etal l)(nine serum (FRS). The gel 
shnwn in Fig. 5.6.1 was inverted digitally and the resulting bands 
measured by densiometr.y. ResuJts are expressed as a percentage 
of maximal digestion. 
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To measure the product jon of matrix metalJoproteinases by wild-type and 
Cd39-null endothelial cells, we measuredMMP activity in the culture rnedia 
after incubation on endothelial cells as well as the MMP activity of purified 
endothelial vesicles. Our 2 experimental conditions were a control group of 
0.5 FBS and a treatment group of lOng/ml VEGF in 0.5 FBS. 
The culture media had no detectable MMP activity even after prolonged (48 
hour) incubation on endothel ial cells (results not shown). This is not 
unsurprising as MMPs usually act locally around endothelial cells and 
significant dillltion would occur after release into the culture media. 
However, after purification of endothelial vesicles from the culture media by 
ultracentrifugation, we were able to detect significant MMP-2 activity. 
Figllre 5.6.3 shows the activity of MMP-2 in wild-type and Cd39-null 
endothelial cells in the control samples and foJ]owing VEGF treatment. 
Surprisingly, VEGF fuiJed to induce increased MMP-2 expression in either 
wild-type or Cd39-null endothelial cells. Control media without endothelial 
cells showed minimal MMP activity (not shown). This contrasts with 
published data that VEGF induces MMP expression in cultured endothelial 
cells. 256 However, in that paper, the researchers used 2.5% serum with 
VECjF, indicating that perhaps the combination of serum and growth factor 
is required for upregulation of MMP expression. 
Importantly, there was no significant difference in the expression of MMP-2 
by wild-type or Cd39-null endothelial cells in either the control or VEGF-
treated groups. In the control group, the wild-type cells had higher 
t~xpression levels (J 00 (!c) in the wild-type vs 70 c/() in the Cd39-null) but this 
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was \lot statistically significant CP=:O.13). This trend was reversed in the 
VEGF-treated group with Cd39-null cells higher (70% in the wild-type vs 
9(Y/(1 in the Cd39-nuJl), but remained statistically insignificant (P=O.17). 
Although preliminary, these results suggest that differences in the absolute 
production of MMPs by wilcl-type and Cd39-null endothelial cells do not 
account for the observed decrease in MMP activity in the Cd39-null 
myocardial inCarct tissue. It is more likely that ilure of inflammatory and 
endothelial cells to migrate into the infarcted tissue in C({N"flU]1 mice 
resulted in a decrease in MMP production in the infarct and protection from 
cardiac rupture. 
However, we do accept that modulation of the MMP system may still be 
responsible ror some of the observed angiogenesis defects of the Cd39-null 
mouse. MMPs are often targeted at the leading edge of migrating cells in 
complex with integrjns,')5,lOLJ and this interaction at the cell surface could be 
affected by deletion of Cd39, without affecting the expression of MMPs in 
secreted membrane vesicles. 
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Control VEGF 
OVlUd ·h.'I! -:-
. Cd J9· r.:J1I 
Figure 5.6.3- Matrix me.taJJoproteinase-2 (l\UlP-2) expression b~i 
wjJd~t)'pe and CJ351-null endotheliaJ rell-deri\'l'd \'esidl's. Control 
group (O.5'k FDS). treatment group (0.5% }'HS plus VEGF 
lOng/mI). i\IMP-2 aC'tivi(~' assessed b)' densitometry anaJ)'Si8 of 
digitall)' inverted zYrDography gels. ResuJts expn'Ssed itS mean of 
three ind(~pendent experiments :t: ... .t.d. Representative zymography 
gels are shown beJow. 
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5.7 HYPOTHESIS: DELE1'ION OF' Cd39 AND 
I)ISORI)EREI) P2-SI(;NAI.JN(; CAUSES 
VASCULAR INTE(;RIN DYSFUNCTION 
225 
To sllmmarize our initial studies of wilJ-type and Cd39-null endothelial 
cells we have shown, firstly, that defects in growth factor signaling and 
cnJothelial cell proliferation are not responsible for the observed 
angiogenesis defects in the Cd3CJ-l1ull mouse. Secondly, we Jemonstrated 
that Cd39-null endothelial cells do not undergo greatly increased apoptosis 
in response to nucleotide stimulation. Finally, we showed that there is no 
major decrease in the secretion of the gelatinase metalloprolein<lses by 
('d39-nulJ endothelial cells. These resu Its all suggest an alternate molecular 
mechanism for the observed defects in in vivo angiogenesis in the Cd39-null 
rnouse. 
A marked decrease in the migration of endothelial cells into implanted 
Matrigel'I'M pJugs was seen in Cd39-null rnice. This suggests that a defect in 
integrin function could exist ill Cd39-null endothelial cells. 
This is an attracti ve hypothesis because P2-receptors have been shown to 
form complexes with integrins at the cell membrane level. For example, the 
purinoceptor P2Y 2 has an RGD sequence in its first extracellular loop, 
suggesting tlwt it may bind to the RGD-binding motif of integrin avf~A)). 
Mutatjon of til is sequence to RGE greatly decreases the colocalization of 
P2Y2 and u vi3/f3'1 and also limits the JOWl1stream signaling of P2Y: to FAK 
following UTP stimulation. J95 
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This suggests that the formation of P2-receptor and integrin complexes are 
impol1.ant for normal P2-receptor signaling, but does not answer whether this 
complex formation is important for integrin function. Both A'fP and UTP 
have been shown to be chemotactic to endothelial cells, which implies a link 
between P2-receptor signaling and integrin function.?04 
We hypothesize that stimulation of endothelial eel ts with nucleotides reslIJ ts 
in the colocal ization of P2-receptors and integrins in large signaling 
complexes at the cell membrane and that this interaction is important for the 
activation and function of integrins (figure 5.7. J). Many integrins are not 
constitutively active, but rather, are expressed on the cell surface in an 
inactive state. For example, the extracellular domain of integrin !1 V [:3 3 is 
folded over in the inactive state, but, upon activation activation, straightens 
and allows interaction of the RGD-binding site with the extracellular 
rnatix. [16 The finding that P2-receptors and integrins interact at the cell 
surface implies that nucleotide-mediated signaling may have a role in 
promoting integrin activation. 
We suggest that the deletion of Cd39 results in increased nucleotide 
concentrations at the cell surface and, subsequently, causes differential P2-
receptor desensitization. This may perturb the activation of various integrins 
by P2-receptors and result in endothelial integrin dysfunction (figure 5.7.2). 
Alternatively, nucleotide-signaling may promote the expression of speci l'ic 
integrins on the cellular membrane (figure 5.7.3). Recent work by 
Kaczmarek et aL, has shown lhat UTP treatment upregu]ates the expression 
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of the (( v-integrin subunit on the surface of human umbilical vem 
endothelial cells (HUVEC). Cd39 deletion and subsequent in vivo 
receptor desensitization may thus result in decreased expression of important 
vascular integrins in the absence of effects on integrin acti vation (figure 
5.7.4). 
riinally, Cd39 itself could form part of signaJing complexes involving P2-
receptors, integrins and growth factor receptors (figure 5.7.5). We have 
recently published that the N-terminus of CD39 interacts with a scaffolding 
rnembrane phosphoprotein, RanBPM. 257 In addition to binding the HGF-
receptor cMET and modulating a number of intracellular signaling 
cascades,m RanBPM also interacts with integrins and may effect integrin 
activation directly.259 Deletion of tbe Cd39 gene may disrupt intcgrin 
function independent of the loss of ectonucleotidase activity (figure 5.7.6). 
[n sumrnary, the observed cellular migration defects in Cd39-null mice 
suggest that the function of variolls integrin receptors might be perturbed in 
vivo III these mice. We hypothesize that integrin function is disrupted 
secondary to P2-receptor desensitization and that this results in either 
decreased activation or decreased expression of integrins at the cell surface, 
AJternatively, important macromolecular cell surface complexes may be 
disrupted by Cd39 deletion independent of the enzymatic function of Cd39. 
'To explore these hypotheses, we measured cellular integrin activity by 
ad!1csion assays and measured downstream signaling pathways Collowing 
integrin ligation. 
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Plumil 
Membrane 
CD39 
ATP.ADP 
UTP. llDP 
\/1/\, 
\1 \; \/( 
" 
COOH J 
Pl-receptor 
Figure 5.7.1 - H)'pothesis No.1 
Integrin 
a(,ti\'ation 
lntegrin 
Nueleutjde attivatlon 0(' P2-reteptor promotes co-lotalizalilUl uf 
purinergk rf"teptors with intt:'grins. This signaling complex r~sllils jn 
acthation of these important angiogenic integrins. In this se.t1ing, CL>39 
sen-'es to protect P2-re('~ptors fn)m desensiti1..a1ion caused hy lo,",'-Ie\'el 
bc1sal nudeotide le\iels. 
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Figure 5.72 - H.\'pothe-sis No.1 
Int(-grin 
inactivation 
Integr1n 
~l~tjon of CdJ9 results in P2-feceptor desensiti1.ation because of 
increased b8('kgmu d nucleotide levels . These desensHi:l~d P2-receptors 
can, therefore. not respond to further JludeoUde signals, and are unable 
to acth'att:' angjog~nic integdns. 
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AMP 
Plasma 
Membrane 
COOH 
CD39 
Figure 5.7.3 - Hypothesis No.2 
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\} , j \'''' '. "J ,. l 
COOl-! ~I 
Pl-receptor 
Gene 
t ranscri pt ion 
Increas{~d 
angiogenic 
responses 
• 
Increased 
integrin 
expression 
Rather than dire-etl)' activating jntegrins. P2-reeeptors may respond to 
nucleotide-mediated signals byincTt'ashlg the expression (.f specific 
angiogt'nk 'ntegrins. Once agHin, CIl39 preserves these purinergic 
signaL~ b)' pre"'cnting P2-receptor desensitization. 
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Once again, d(:'ll:",tjon of Cd39 remits in P2-re('eptor d(:'sen.,itiz:ation 
because of jncrea~d bflekground nudeorjde le,'cls. These desensHized 
P2-receptors can. therefore. not respond to further nucJefJtide signals, 
and are unable 10 induce inneased expressjol. of angiogenic 'n(£'grins. 
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COQH COOH 
GrowtJl 
P2-r't'('eptur CD39 lHtegrin Factor 
r~eep{()r 
CELL lVIE1\,IBRA.NE 
SIl;NALING COMPLEX 
Figure 5.7.5 - H~'poth('s's No.3 
Th(' final hypollil'Sis posits thai CD39 forms an integral structural of an 
important ceH surface signaling complex in\'olving integrins. Pl-
receptors and growth factor .l"el'eptors. 
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Figure 5.7.6 - H~'pothesjs No.3 
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(}elellon of Cd39 rna)' then pren'nl the structural ass~mbly of (his 
putatiw signa Ii ng complex, with resuJting disruption of gro\.~ th farlor 
signaling and integrin arti\'ation. 
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5.8 ADHESION ASSAYS 
5.8.1 Introduction 
Cell adhesion to extracellular matrix is a crucial process in a number of 
pbysiological and pathological conditions, including wound-healing, blood 
coagulation, tumour angiogenesis and tumour metastasis. The primary group 
of receptors regulating attachment to extracellular components is the integrin 
family of heterodimeric transmembrane receptors. In addition to providing 
structural support to cells, integrin-mediated cellular adhesion induces a 
range of intracellular signals that regulate cellular survival, proliferation and 
differentiation. J·t 
As djscllssed above, the P2-receptor P2Y2 co-localizes with integrin o.vl3, 
and this interaction has been shown to be important for the normal function 
of P2Y 2. 19.' However, it was not reported whether this integrin-purinoceptor 
interaction is also required for norma] uvl5, activity. 
We suggest that the binding of P2Y2 to Ct. V I"3 3 promotes the activation of 
integrin Ct.vl.)j to its ligand-binding state. Deletion of Cd39 and the 
consequent decrease in endothelial ectonucJeotidase activity would lead to 
elevated nucleotide concentrations at the endothelial membrane. This may 
result in desensitization of P2Y2, preventing the normal interaction of P2Y 2 
with integrin (XvI), and result in vascular integrin dysfunction. 
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Considering the beterogeneity of integrin subunit interactions and the 
multiple purinoceptors expressed by endothelial cells, it is entirely possible 
that several important integrin-purinoceptor interactions are disrupted by 
deletion of C'd39. Increased nucleotide concentrations at the endothelial cell 
sllrface could cause differential desensitization of various endothelial 
purinoceptors and lead to complex alterations in endothelial integrin activity. 
Thus, nucleotide-mediated integrin dysfunction may explain the cellular 
rnigration defects, and hence the angiogenesis defect, observed in Cd39-l1u II 
mIce. 
During angiogenesis, a number of important angiogenic integrins are 
upregulated by the actions of various growth factors. 34 The finding that UTP 
promotes the expression of the <xv-subunit suggests that nucleotide-mediated 
signaling may have important roles in altering vascular integrin expression 
profiles during angiogenesis. 20 ,j 
The major UTP receptors on endothelial cells are P2Y2 and P2Yej.2f7 P2Yj , 
ane[ to a lesser extent P2Y2' rapidly desensitize following treatment with 
UTP,IXO which suggests that UTP-induced responses may be dampened in 
Cd39-null endothelial cells. If UTP treatment does indeed upregulate (X y -
integrin expression in rnurine microvascular endothelial cells, one would 
expect decreased upregulation, or even decreased baseline expression, of (Xv 
in Cd39-nuH endothelial cells. 
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Cd3<J deletion and P2-receptor desensitization may thus result in decreased 
surface expression of important vascular integrins, including CJ:vf33/[\, and 
cause tbe observed defects in endothelial cell migration. 
In addition, the cleveloprnent of large signaling complexes on the surface of 
endothelial cells is thought to be important for the coordination ofmultip1e 
signal ing inputs. In this context, P2·receptors, integrins and growth-factor 
receptors fonn important cell··membrane signaling complexcs.I<)) 1<)3 Cd39 
binds RanBPM, a scaJlolding membrane phosphoprotein with known links 
to integrins, including LFA-l (lymphocyte function-associated antigen-
1).257.25(J In addition, Cd39 undergoes palmitoylation and targeting to lipid 
rafts, called caveolae, and rnay thus form part of important signaling 
complexes invol ving integrins. 198 
Deletion of Cd39 could disrupt these signaling complexes independent of 
the loss of endothelial ectonucJeotidase activity. The loss of this structural 
role Cor Cd39 in macromolecular signaling complexes may explain the 
observed cellular migration defects in Cd39-null mice. 
'fhe measurement of eeJ lular adhesion to various matrix strata is considered 
one of the simplest, but most direct, assays of integrin function. In order to 
ascertai n, firstly, whether i ntegrin dysfunction occurs in C d3 9-nuU 
endothelial cells, and, secondly, which integrin function is defective, we 
tested the adhesion of wild-type and Cd39-null endothelial cells to a Humber 
or' matrix components, inc.iuding gelatin, fibronectin and vitronectin. 
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Gelatin is a heterogeneous rmx of high-molecular weight, water-soluble 
proteins derived from coUagen. 260 The integrins nIf)1 and c(2131' in particular, 
bind to these collagens.3~ 
Fibronectin is an extracellular matrix protein with a wide tissue distribution. 
It is present as a fibril1ar network in the ECM and as soluble protorners in 
body fluids. In total, 10 different integrins have been shown to bind to 
fibronectin via either its RGD-sequences or to various secondary binding 
sites>'61 Because it contains a number of RGD-seq uences, it binds the 
important angiogenic i ntegrins (x:d:~ I and lXv f),.34 
Vitrol1cctin is a single-chain glycoprotein present botb in plasma and bound 
to the extracellular matrix. Its structure is divided into a number of domains 
including the somatomedin B (SMB) domain, which binds the protease 
inhibitor PAl-I, and a connecting region with a single ROD-sequence. By 
binding PAl-I, matrix-associated vitronectin has a role in regulating 
extracellular proteolysis.262 It also binds integrins et.vf33 and o.vBs by its single 
RG D-seq uence. 26:1 
Therefore, by testing the adhesion of wild-type and Cd39-null to these 
important extracellular matrix components, we expect to test the function of 
a number of different vascular integrins. 
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S.S.21\1ethods 
a) Adhesion assays 
.. 96-well plates were coated overnight at 3rC with gelatin (' ~!g/ml), 
vitronectin (3~lg/ml) or ribronection (40f!g/ml). Prior to use, the wells 
were washed once with PBS then blocked with I (X) bovine serum 
aJbumin (13SA) for 2 hours at 4°C. 
• Wild-type and [\l39'-11ulI endothelial cells were grown to 70% 
confiuence and serum starved in O.Sllo FBS overnight before use. 
• In the apynlse pre-treatment experiments, endothelial cells were pre-
treated with Grade VII apyrase (5units/ml) for 6 hours. 
.. Endothelial cells were detached by trypsinization, the trypsin 
neutraJized'vvith soybean trypsin inhibitor and the cens resuspended in 
serum-free media. The cells were then spun down to a pellet at 1000 
rpm for 5 minutes and the supernatant discarded. 
.. The endothc1i;'ll cells were then counted and resuspended in a volume 
of serum-free media corresponding to 30000 cells / I OO~d. 
• For integrin activation experi ments, MnC12 (500p, M) or PMA 
(100nM) was added to the sampJes and incubated with the endothelial 
cells at 3TC for 15 minutes pdor to plating. 
.. 30 000 cells were added per well of the 96-well plate and inclIbated at 
3rC for 1 hour. 
.. After I hour, the media was carefully removed from the plates and the 
adherent celi,,, washed once with PBS. 
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.. A pen~oll solution was then added to the cells to lift poorly attached 
cells by density gradient. The percoll solution consist 73m1 percoll 
(density 1.13mg/ml. Amersham Phannacia Biotech), 27ml distilled 
water and 900mg NaCl. 
.. The cells were then washed twice with PBS. 
.. The adherent cells were then fixed with methanol for 30 minutes at 
room temperature. 
.. After fixation, the adherent cells were stained with 0.5 crystal violet 
in 20 C}{7 methanol for 30 minutes at room temperature. 
III The plates were then washed thoroughly with distilled water and the 
absorbance measured at 560nm using a microtitre plate reader. 
.. Resul ts arc expressed an as average of three experiments ± standard 
deviation. 
h) lntegrin expression hy imlnunoprecipitation and 'Vestern 
blot analysis 
.. Wild-type and Cd39-null endotheLial cells were grown to 70% 
confluence and serum starved in 0.5 FBS overnight before use. The 
cultured endothelial cells were then treated with lOO[!M UTP for 0, 2, 
4 or 6 hours. 
.. The adherent cens were collected in a 300~,tl solution of Jysis buffer, 
centrifuged at 14000 rpm for 10 minutes, tbe supernatant conserved 
and the nuclear pellet discarded. 
.. Sample protein concentrations were determined using the Biorad DC 
Protein Assay. 
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• 20pL anti-ctv antibody was added to 300p,g protein aliquots diluted in 
400pL PBS, and incubated on ice for 30 minutes. 
J5p.L protein A-coupled scpharose beads (Sigma-Aldrich Corp. SL 
Louis, MO) vvere added to the mixture and incubated on ice for 60 
minutes with frequent mixing. 
• The protein A-coupled sepharose beads were separated by pulse 
centrifugation and then washed in PBS to remove unbound antigen. 
• The samples were boiJed in SDS-PAGE Sample Buffer containing 2% 
!3-mercaptoethanol. 
• Western blot anaJysis was performed as described in 5.2.1 (c), using 
anti-ely antibody (1:] 000 concentration) as the primary antibody. 
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5.8.3 Results and discussion 
a) Decreased adhesion of Cd39~nun endothelial cells to 
vHronectin. 
We studied the adhesion of wild-type and Cd39-null endothelial cells to cel1-
culture plates coated with different extracellular matrix proteins. Figure 5.8.1 
and Table 5.8.1 compare the adhesion of wild-type and Cd39-nulJ 
cndothelial cells to gelutin-, fibronectin- and vitronectin-coated cell culture 
plates. 
There was no difference in tbe attachment of wild-type and Cd39-nu Il 
endothelial cells to gelatin (wild-type 75.S±30.6(/c) vs. Cd39-l1ull 59±13.2 . 
P=O.22) or to fibronectin (wild-type 7S.8±30.5% vs. Cd39-l1u11 7S.6± 17.MVc;. 
P=O.50). However, there was a significant defect in the adhesion of Cd39-
null endothelial cells to vitronectin (wild-type lOCh] 2.3 1;70 vs. Cd39-nuH 
4S.2±24.9(y(), P=O.O 13). 
This implies a specific defect in the function of the important angiogenic 
integrins (Xvf\ and l"Xvf\ in Cd39-nul1 endothelial cells. The finding that 
Cd39-nul1 cndothelial cells bind normally to ribronectin may initially appear 
to contradict these results because ct vI3,1f\ binds to fibronectin via its 
mUltiple RGDbindi ng sites. However, fibroncctin also binds a number of 
other inlegrins by its RGD-·sequences and via various secondary binding 
site.2()i Therdore, Cd39-null endothelial ceUs may bind fibronectin with 
other normally-Cunctioning integrins even though o.vf3:/f35 are dysfunctional. 
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Table 5.8.1: Endotl1(~lial cell adhesion to various extracellular matrix 
proteins. Wi]d-type and Cd3 null endothelial cells were aHowed to attach 
to 96-well plates coated with gelatin (I ~lg/ml), fibronectioll (40~.g/ml), or 
vitroneClin (3~tg/m1). Results expressed as a percentage of maximal adhesion 
± standard deviation. 
Wild-type 
Cd39-nuU 
P-values 
Fig 5.8.1 
s::: 120 
o .-
ID lOO 
J: 
'1l 
III 80 
(1.1 
U 50 
III .-
(1.1 40 
J: ...-
o 20 
'1l 
s::: 
W 
GeJatin 
.5±30.6(!~i 
59± I 3.2 
0.22 
Gelatin Fibronectin 
Vitroncctin 
lOO± 12.3 
45.2±24.9% 
0.013 
-* 
Vitronectin 
: [] Wild-type 
III Cd39-null . 
Figure 5.8.1 - Wild-type and C'd39-null endothelial adhesion to collagen, 
fibronectin and vitronectin.Results expressed as a percentage of wild-type 
adhesion to cullagen ± S.e.Ill. *, P<O.05. 
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Indeed, 13;-null endothelial cells have been shown to adhere normaJly to 
fibronectin in the face of significantly decreased adhesion to vitronectin. 129 
'['his emphasizes the crucial importance of integrins C1 yI3:/(\ in mediating, 
specifically, cellular adhesion to vitronectin. 
b) Decreased vitronectin adhesion of Cd39-nuU endothelial 
ceUs occurs hecause of decreHsed integrin Hctivation, not 
decreased integrin expression. 
Previous experimental evidence has demonstrated that purinergic signaling 
has important roles in promoting both integrin activation and inlcgrin 
expression. C]'he decreased adhesion of Cd39-null endothelial cel to 
vilronectin may, therefore, be caused by either decreased expression or 
decreased activation of Ctvf)/I\. 
We measured the surface expression of the uy-integrin sllbunit on the 
surface of wild-type and Cd39-null endothelial cells by immunoprecipitation 
and Western blot analysis. In addition, because UTP was shown to increase 
tbe expression of the av-subunit in HUVECs, we tested the effect of UTP 
treatment on wild-type and Cd39-null murine pulmonary endothelial cells. 
Fig S.R.2 shows the expression of the C,(y-integrin subunit in wild-type and 
Cd39-null endothel ial cells at baseline in culture and after 2, 4, or 6 hours 
treatment with I OO~IM u'rp. These results demonstrate 2 important findings. 
Firstly, it can be seen that there is no difference in the expression of the c,"y-
integrin subunit in wild-type and Cd39-nuU endothelial cells at baseline. 
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crhis is ilnponant because the exv-subunit is required for both o.vl1j and ay~S 
assembly and is crucial during the process of cellular adbesion to 
vitronectin. Although we have not confirmed that no difference exists in the 
endothelial expression of integrin I:)~- and 13 s-subunits between wild-type and 
Cd39-nulJ endothelial cells, the finding that there is no difference in U y 
expression raises the possibility that differences in integrin activation, rather 
than integrin expression, account for the observed defective adhesion of 
Cd39-nulI cells to vitronectin. 
Secondly, it can be seen that treatment with UTP does not increase the 
expression of the ctv-integrin subunit in either wild-type or Cd39-null cells. 
'T'his contradicts the finding of Kaczmarek et aL that UTP significantly 
upregulates the expression of (Iv in HUVECs?O~ Possible explanations for 
this discrepancy include the use of a different population of endothelial cells 
(human umbilical vein endothelial cells vs. murine pulmonary endothelial 
cells), or different experimental protocols used. Kaczmarek et al. determined 
uy-intcgrin expression by We tern blot analysis of whole cdllysates. while 
we used immunoprecipitation to purify the o.v-integrin suhunit prior to 
analysis. The (J.y-integrin subunit was expressed at too Iowa level to be 
detected by Western blot analysis of whole cell Iysates in our experiments 
(results not shown). 
Alternatively, these findings could be represent experimental error because 
or satll ration of the primary anti-u y antibody. In future, we should repeat 
these experiments using titrations of the primary antibody to confirm that 
excess antibody has been added. In the meantime, we feel confident that our 
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data doe:s represent a true finding in that: firstly, 20pL of anti-<xv antibody is 
likely sufficient given the low expression of intcgrin <Xv in vitro; secondly, 
this data is cOl1sistent with our intial experiments showing no difference in 
expression via (Lv immunofluorescence; and, finally, the data is con,sistent 
with the hypothesis of integrin desensitization presented below. 
As discussed previously, because lJ'TP receptors are thought to be 
desensitized in C d3 9-nul1 cndothel ial cells, the control of ctv-integrin 
expression by UTP vvould provide an important link between nucleotide-
mediated signaling and intcgrin function. If the surface expression of the Cl.v-
integrin subunit was promoted by UTP, we would expect increased surface 
expression of a v in wild-type endothelial cells, compared with Cd39-null 
cells. However, we have shown, Cirstly, that there is no difference between 
the expression of tbe uy-integrin subunit in wild-type and Cd39-nuH 
endothelial cells at baseline, and secondly, that UTP does not upregulatc the 
expression of U v in murine pulmonary endothelial cells. 
We, therefore, propose that Cd39-null endothelial cells have defective 
attachment to vitronectin because of decreased acti vation of U V P3 and/or 
UVP.'i integrins. Further proof of this hypothesis was obtained by the finding 
that non-specific integrin activation corrects the adhesion of Cd39-null 
endothelial cells to vitronectin. 
Mnel} is a polent effector of a number of integrin-mediated adhesion events 
and lS thought to activate integrins by binding to specific cation-binding sites 
and inducing conformational changes in the ligand-binding site::64 
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Table 5.8.2 and figure 5.8.3 shows the effect of MnCI2 treatment on the 
adhesion of wild-type and Cd39-nuJI endothelial cells to vitronectin. As 
shown previously, Cd39-null endothelial cdl adhesion to vitronectin was 
significantly decreased compared with wild-type cells (wild-type lOO± I 'Nfl) 
vs. Cd39-null 57.3±23.2':1). P=O.O II). [n keeping with our hypothesis that 
n.Vr~,IP5 activation is decreased in Cd39-null endothelial cells,M nCll 
corrected the defecti ve adhesion of Cd39-null endothelial cells to vitronectin 
(wild-type plus MnC12 101. J±S.9(YrJ vs. Cd39 .. null plus MnCI] 9S.4±8.6%. 
P=O.198). MnC12 treatment was associated with a statistically significant 
increase in the adhesion of Cd39-l1ul] endothel ce1\s to vitronectin (Cd39-
nuH control S7.3±23.2(jb vs. Cd39-null plus MnC12 9S.4±8.6%. P=OJl22), 
but had minimal effect on wild-type cells (wild-type IOO±IS.7 vs. wild-
type plus MnCL2 JOl.l±5.9%. P=0.458). 
This shows that normal integrins are expressed on the surface of Cd39-null 
endothelial cells, but that they are not fully functional because of decreased 
integrin acli vation. It also implies that P2-receptors have an important role in 
activating important angiogenic integrins. 
As discussed in the literature review, extracellular l1ucleotides signal through 
type-·2 purinergic (P2) receptors called P2Y (G -.- protein coupled) or P2X 
(ligand gated ion channeIs).265 Most P2Y receptors activate phospholipase C 
(PLC), resulting in the formation of inositol 1,4,S-triphosphate OP.,), 
diacylglycerol (DAG) and the mobilization of cytosolic Ca2+. This results in 
the activation of an important intracellular signaling molecule protein kinase 
C (PKC) and has been implicated in integrin activation.266.267 Phorbol 12-
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myristate 13-acetate (PMA) is an amLlogue of DACI,268 which has been used 
in l1111nerOUS experimental settings to activate integrins by binding PKc.269,nll 
Our hypothesis is that excess nucleotides at the cellular surface in Cd39-null 
cells, results in desensitization of P2-receptors and in secondary defects in 
in1egrin activation, perhaps via defective PKC activation, For this reason, we 
studied whether we could correct the defective adhesion of Cd39-n u II 
endothelial cells to vitronectin by using PM A to activate protein kinase C 
(PKC). 
Table 5.8.3 and figure 5.8.4 shows the effect of PMA on the adhesion of 
wild-type and Cd39-null endothelial ceLls to vitronectin. It can be seen that, 
while PM/\' increases the adhesion of Cd39-null endothelial cells to 
vitronectin, this increase is not as great as that induced by MnC12 treatment. 
PMA treatment increases the adhesion of Cd39-null endothelial cells from 
57.3 to 81.5 of wild-type adhesion, but this increase is not statistically 
significant (P::::O.078). 
Despite repeating this experiment numerous times, we could not prove that 
PMA-induced activation of PKC corrected integrin dysfunction in Cd39-nuJl 
endothelial cells. Decreased PKC activation in Cd39-null cens may still be 
invol ved in the defective adhesion of CJ39-null cells to vitronectin, but 
alternate intracellular signaling molecules mllst also playa role in 
nuc leoti de-mediated integri n acti valion in wi Id-type and C d3 9-nuU 
endothel ial cells. It is possible that several P2-receptors, each activating 
different intracellular signaling pathways, work in tandem to activate 
integrins during angiogenesis. 
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c) Defective integrin function in Cd39-nuH endothcHal ceUs 
occurs because of decreased nucleotide hydrolysis. 
As discllssed above, Cd39 deletion may result in integrin dysfunction 
secondary to either, loss or ectOI1Llcleotidase activity and P2-receptor 
desensitization, or by structural disruption of integrin function in 
macromolecular signaling complexes. For this reason, we replaced the 
ectoenzyme function of Cd39 by pre-treating wild-type and Cd39-null 
endothelial cells with Gracle VII apyrase for 6 hours. 
Grade VII apyrase is a soluble enzyme with significant adenosine 5'-
triphosphatase and adenosine 5' -d ipbosphatasc activity, which was purified 
from potato (S. tuberosum). Different apyrase isoenzymes with differing 
ATPase/ ADPase ratios have been isolated from potato.271 Grade VU apyrase 
was used because, since it has a low ATPasc/ADPase ratio, it approximates 
the enzymabc function of CD39. 
Pretreating Cd39-null cells \vith soluble Graue VU apyrase would replace 
the ectonucleotidase function of Cd39, limit the pericellular accumulation of 
high nucleotide concentrations and, thus, allow desensitizeu P2-receptors to 
resensitize. [J P2-receptor desensitization is responsible to the integrin 
dysfunction of Cd39-null endothelial, this treatment should correct that 
dysfunction. 
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Table 5.8.2: Endothelial cell adhesion to vitmnectin following treatment with 
MnCJ2• Wild-type and Cd39-null endothelial cells were aj]owed to attach to 96-
well pl:Jtes coated with vitroncctin (3p.g/ml) in the presence or absence of 500~lM 
Control 
Wild-type lOO± 15 
Cd39-nuH 
P-values 0.0 l 0.20 
Table 5.8.3: Endothelial cell adhesion to vitronectin following treatment with 
PVIA. Wild-type and Cd39-null endothelial cells were allowed to attach to 96-well 
plales coated with vitronectin (3~lg/ml) in the presence or absence of 250~tM 
PMA. 
Wild-type 
Cd39-null 
P-valucs 
Control PMA 
lOO±15 
S7.3±23.2i)b 81.5±1O.1 
OJn 
Table 5.8.4: Endothelial cell adhesion to vitront~etin following pre-treatment 
with apyrase. Prior to the adhesion ~lssay. wild-type anel Cd39-nul1 endothelial 
cells were treated with grade VB apyrase (511nits/ml) for 6 hours. 
1"-- ------
Control Apyrase 
1-,,-
Wild-typ(~ I OO± 1 5.7 (1(1 95.3± [5.6% 
1- .. _-----
Cd39-null 5 .3±23.2 98.9±20.3cYr) 
1-
P-values 0.01 0.40 
c ... 
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l+ -/- +1+ -/- 1' /+ . 1'. +/+ .,'-
Cl.v Inregrln 1201<0a 
o 2 4 6 UTP 100JlM (hours} 
Figure 51'.2 - u,-integrin ~UbUllif ~xpression in wild-t~'pe (+1+) and 
CdJ9-null (-1-) endoth~ljaJ cells llJ' immunoprcdpitation and 
Western-blot analysis. Cells were tl'1:'<'tted with (ITP (100~M) fot 0, 
2,4, and 6 hours. 
I:: 
.2 l2C 
III 
11/ 
• l oe 
'tI 
III 
= ~; C 11/ 
I,) 
'iii 6C -
* 
Control MnCI2 
r:w I(I -!)'p-oc 
_«139·"JII 
f'lgure 5.8.3 - \Vjld~t~'pe and CcU9-nuJl endotheliaJ cell adhesion to 
\'itronedin folJowing treatment with MnCI! (500J,lM). Result..; 
expr('ssed as a ~r('entage of wild type adhesion to \'itronectin 1: 
s.e.m. "', P<41.05. (Wild-type rontrolvs. CdJ9-null {'ontroll. 
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figure 5.8.4 - Wild.:lype and CJ39-lIull endotheLiaJ tell ad.hesion to 
\'itronedin following treatm~nt with PMA (lOOnM), showing 
partial corn'ction of the defrtth'e adhesion of Cd39-null 
endothelial cells to \'itronectin. Results expressed as a pertentage 
of wild type adhesion 10 vitronrttin ±" s.e.m . .:1:. 1'<0.05. (\Vild.-t~,'pe 
controJ \is. CdJ9-JlUU control). 
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f'jgure S.H-.5 - 'ViM-type and CdJ9-nuH endothelial telJ adhesion to 
vitronectin following 6-h,)ur pre-treatment with soluble Gr •• de VII 
apyrase (Suni1s:JmJ). Results expressed as a per('entage of wild t)'pt' 
adhesion to vitronectin ± s.e.m. *-, 1'<0.05. (\Vild-type control \!S .• 
Ctl39-null contraJ). 
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5.9 INTEGRIN·MEDIATED INTRACELLULAR 
5.9.1 Introduction 
Integrins mediate cell-cell and cell-matrix interactions, and transduce signals 
from the extracellular matrix that modulate cellular growth, differentiation 
and migration. However, integtins have very short intracytoplasmic domains 
devoid of enzymatic activity and thus transmit extracellular signals by 
recruiting intracellular signaling molecules into signaling complexes. These 
complexes, known collectively as focal adhesions,115 connect integrins to 
both intracellular kinases and to the cytoskeleton, in a process known as 
"outside-in" signaling (Figure S .9.1). We have demonstrated specific integrin 
defects in Cd39-null endothelial cells, implying defective activation of a 
number of important intracellular mediators wlth specific actions during 
angiogenesis. 
One of the most important lular signaling kinases with a crucial role 
in focal adhesion assembly and, hence, integrin-mediated signaling is focal 
adhesion kinase (FAK). After being 'recruited to focal adhesions, FAK 
autophosphorylates Tyr397, creating a binding site for the Src homology 2 
(SH2) domain of Src or Fyn. The Src kinase then phosphorylates a number 
of focal adhesion components, including 
and tensinYz 
cytoskeletal proteins paxillin 
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The importance FAK in cellular migration is demonstrated using FAK-/-
fibroblasts, which migrate poorly and have an increased number 
prominent focal adhesion complcxcsY3 FAK functions as an intcgrin 
scaffold which, by recruiting Src to focal adhesions, positions this kinase 
close to cytoskeletal proteins and intracytoplasmic signaling molecules that 
are crucial for cellu migration.274 For example, activation of FAK and Src 
results in the activation of Rac, a molecule vital for lammelipodial 
extension. 275 
FAK also activates phosphoinositide 3-0H kinase (PI 3-kinase) and Akt, 
directly or through Src. Although numerous signaling pathways 
activate Akt, each with differing cellular functions, the activation of Akt 
following integrin ligation is thought to be important for the induction of 
cellular survival pathways and prevention of anoikis (cellular death 
occurring in the absence of binding to the ECM).276 The excess endothelial 
cell apoptosis noted in Cd39-null mice following liver regeneration could 
possibly be caused by a defect in integrin signaling to Akt. 
Finally, FAK has a role in the activation of mitogen activated protein kinases 
(MAPK). The MAPKs are a family of serine-threonine protein kinases, 
which are activated by a range of growth hormones, cytokines and 
cxtracellular matrix components.277 The p42/44 MAPK (also known as 
ERK1I2) modulates angiogenesis on several levels. Firstly, activation of 
ERK1I2 protects endothelial cells from apoptosis and promotes proliferation 
by promoting entry the cell cycle. 242 Secondly, ERK1I2 has been shown 
to promote VEGF expression by increased VEGF gene transcription.278 In 
this context ERK1I2 also phosphorylates HIF-la, suggesting a link between 
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growth factor-induced and hypoxia-induced upregulation of pro-angiogenic 
factors. 279 Thirdly, in addition to modifying expression, ERK1I2 may 
regulate endothelial cell migration by phosphorylating cytoskeletal 
pro teins. 280 
Integrin ligation and activation of F AK is vital for ERK1I2 signaling. 
Placing cells in suspension prevents growth-factor mediated activation of the 
MAPK cascade, while adhesion of cells to extracellular matrix in the 
absence of growth factors stimulates MAPK activity. However, the nature of 
integrin signaling to MAPK is not entirely understood and probably differs 
in different circumstances. 
One suggested mechanism is that cell adhesion stimulates the translocation 
of Rac to the cell membrane and results in the subseq uel1t activation of 
phosphorylation of MEK then leads to downstream MAPK 
activation. 281 Another possible Link is that Src phosphorylates FAK at 
Tyr925, creating a binding site for the adaptor Grb2 and mSOS. This results 
in stimulation of the cascade via the activation of Ras.282 
We have shown that defective endothelial cell migration in Cd39-null mice 
during is associated wjth specific defects in integrin function. 
However, we have not demonstrated which downstream intracellular 
mediators are affected by this integrin dysfunction. Therefore, we measure 
the activation of FAK, Akt and ERKl/2 following vitronectin-mediated 
integrin ligation in wild-type and Cd39-null endothelial cells. Each of these 
intracellular mediators has important roles in endothelial behaviours during 
angiogenesis whether by promotion of focal adhesion assembly, by 
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protection from apoptosis or by promotion of endothelial migration and 
differentiation. 
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PI-3 kinase 
Figure 5.9.1 - FAK signaling 
Vitronecti n 
RGD RGD 
Integrin binding to vitronectin induces integrin clustering and targeting 
of FAK to focal adhesions. FAK autophosphorylates at Tyr397, resulting 
in binding of Src via its SH2 domain. This results in activation of Akt via 
PI-3 kinase. MAPKs (including ERK1I2) are activated either by Rac 
translocation to the cell membrane and downstream PAK activation or 
by mSOS-induced activation of Ras. 
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5.9.2 I\1ethods 
.. Wild-type and Cd39-nul1 mouse lung endothelial cells were cultured 
to 70 confluence in normal endothelial media. Prior to 
experimentation, the cells were starved overnight in a basal media 
containing O.S fetal bovine serum (FBS) and no endothelial 
mitogen. 
.. For the apyrase pre-treatment experiments, the cells were treated with 
Gr::lcie VII apyrase (Sunits/ml) for 6 hours prior to experimentation. 
.. 6-well plates were pre-coated with O.Sf.tg/m1 vitronectin overnight at 
3rc. 
.. The following day, wild-type and Cd39-null endothdial cells were 
detached using a 0.05% trypsin solution. After detachment the trypsin 
was neutralized with soybean trypsin inhibitor and the cells 
resuspended in serum-free media. 3xlOs cells were added to each 
vitronectin-coated plate. 
.. The zero minute control samples were spun down at 1000rpm for 5 
minutes and the pellet immediately placed on ice. 
.. At 15, 30 or 60 minutes the media in the 6-well plates were removed 
by suction and the adherent cells collected in a 120~d solution or lysis 
buffer, centrifuged at 14000 rpm for 10 minutes, the supernatant 
conserved and the nuclear pellet discarded. 
.. Western blot analysis was then performed as described in S.2.1(c) 
using anti-phosphoFAK (phosphoTyr397), anti-phosphoERK 1/2 
(phosphoThr202/Tyr204) or anti-phosphoAkt (Ser473) as primary 
antibodies (I : 1000 concentration). 
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Restore Stripping Buffer (Pierce Biotechnology, Inc. Rockford, fL.). 
Prior to further prohing with antibody, the stripped membrane was 
developed with SupersignaJ chemiluminescent substrate (Pierce 
Biotechnology, Inc. Rockford, IL,.) to confirm that no residual signal 
remained. 
.. The membrane was then reprobed with antibodies to FAK, ERK I 12 or 
Akt to measure the total protein expression of these signal ing 
molecules in each sample. 
.. Results are expressed as the ratio of phosphorylated FAK, ERK 1 12 or 
Akt, to total FAK, ERK 1/2 or Akt at each time point for three 
independent experiments. 
5.9.3 Results 
The finding that Cd39-null endothelial cells have defective adhesion to 
vitronectin, implies specific integrin dysfunction and suggests disordered 
integrin-mediated intracellular signaling. Using phosphospecific antibodies, 
we studied the activation of the focal adhesion kinase (FAK), extracellular 
signal-regulated kinase 112 (ERKI 12) and Akt following vitronectin-induced 
intcgrin ligation in wild-type and Cd39·-null endothelial cells. In each 
experimental group, results are expressed as the ratio of phosphorylated 
(activated) mediator to total mediator at 0, 15, 30 and 60 minutes aCter 
plating onto vitronectin. 
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In keeping with ollr finding that there is defective adhesion of Cd39-null 
endothelial cells to vitronectin, we have shown that plating of Cd39-null 
endothelial cells onto vitronectin results in defective activation uf .FAK and 
downstream ERK 1/2. 
Figure 5.9.2 shows the phosphorylation of FAK at tyrosine 397 at variolls 
time points after plating willl-type and Cd39-nul1 endothelial cells onto 
vitroncctin. in wild-type endothelial cells, FAK is strongly activated by J 5 
minutes and this phosphorylation is sustained for 60 minutes. In contrast, 
Cd39-nuJl cells have poor and delayed activation of FAK. Cd39-null 
endothelial cells have a statistically significant decrease in activation of FAK 
at 15 minutes (wild-type LO(H;(! vs. Cd39-null 58%. P=O.013), and at 30 
minutes (wild-type 74(1() VS. Cd39-11Ull 36%. P=O.O 17) after vitronectin-
plating. By 60 minutes arter plating, phosphorylation of FAK in Cd39-nu!1 
cells remains decreased compared with wild-type levels, although this result 
rails to achieve statistical significance. (wild-type 64(}{) vs. Cd39-null 42 
P=O.06). 
Cd39-null endothelial cells also have defective activation of downstream 
ERKI/2 Lll'ter plating on vitronectin (Figure 5.9.3). In wild-type endothelial 
cells, ERKI/2 has little phosphorylation after 15 minutes, but becomes 
strongly phosphorylated after 30 minutes and remains phosphorylated until 
60 minutes. This delay 1n activation relative to FAK is in keeping with 
ERK 1/2' s duwnstrearn position in the signal ing cascade. 
Cd39-null endothelial cells show decreased phosphorylation of ERK 1/2 after 
plating onto virronectin. Activation or ERK I 12 at 30 minutes was 
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approximately half as efficient in C'd39-null compared with wild-type 
endothelial cells (wild-type 10CY/f) vs. Cd39-llull 51 . P=0.0015). By 60 
millutes, Cd39-null cells achieved almost equal activation of ERKII2 
relative to the wild-type cells (wild-type 91 vs. Cd39-nul1 8(YYrJ. P=O.28), 
indicating that a kinetic delay exists in (J.vl)jf:3 5 integrin-mediated signaling 
in C'd39-null endothelial cells. 
Marked differences in FAK and ERK1I2 activation are noted at baseline in 
wild-type and Cdj'9-null endothelial cells. FAK has increased activation in 
wild-type cells vs Cd39-nul1 cells at baseline (wild-type 24.8 vs. Cd39-
null O.3(k. P=Cl.04). In contrast, ERK l/2 is increased in unbound Cd39-null 
cells. (wild-type 2.7/10 vs. Cd39-null 26.4/~). P=O.Ol). A possible explanation 
for this is that FAK is activated in wild-type cells by tbe paracrine release of 
extracellular nucleotides, acting via P2-receptors, which have been 
desensitized in Cd39-null cells. In contrast, ERK1I2 may be activated at 
baseline by a P2-receptor, which is not readily desensitized, like P2Y6' 
Stimulation of this receptor would be greater in Cd39-null ceLls because of 
deletion 01' the bulk of cellular ectonllckotidase activity. 
Further work is required to determine the mechanisms underlying these 
differences in unstimulated cells, however, it is worth noting that the 
addition of soluble apyrase abolishes these differences in vitro (vide in rra). 
This suggests that deletion of the ectonucleotidasc effect of Cd39, rather 
than any structural effects of the protein, are responsible for the observed 
differences in Cd39-nul1 ceUs. 
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Figures 5.9.2 anti 5.9.3 . Graphs represent ph(}''''phor~·lation of 
FAK (Fig 5.9.1) and ERK1I2 (Fig 5.9.3) jn wild-type and Cd39-nuJJ 
endothelial ceUs at 0, IS, 30 and 60 minutes afl('rplating Ohto 
vitronectin. Bar charLo; r('present dt.'usitometr." reSuJts (means :t: 
s.e.m) of phosphor)'lat€d }'AK or ERK1I2 di\'ided h~' tota] }'AK or 
ERKIJ2, res Pffl l\ieJy . 'Representative blots .ttl' shown below 
graphs. *,1'<0.05. 
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We had previollsly hypothesized that defective activation of Akt may be 
responsible for the increased endothelial cell apoptosis in regenerating livers 
of Cd39-null mice. However, following ligation of (he (:Xvf)]![)s integrin, 
wild-type and Cd39-null endothelial cells showed similar phosphorylation of 
Akt (Figure 5.9.4). Both wild-type and Cd39-null cells had initial 
submaximal activation of Akt at 15 minutes (wild-type 76% vs. Cd39-null 
65 . P::::0.44), and then sustained activation at 30 millutes (wild-type IOfYVrJ 
vs. Cd39-l1ul1 96 t}L ]>::::0.45), and 60 minutes (wild-lype 96(Yr; vs. Cd39-11U II 
83 P=O.36). 
'1'hc fact that there is no significant difJCrence in the phosphorylation of Akt 
in wild-type and Cd39-null cells implies, firstly, that defective activation of 
A kt is not responsible for the endothelial cell apoptosis during ~Ulgiogenes]s 
in regenerating mouse livers in Cd39-null animals. Second]y, it suggests an 
aJded complexity to the defective integrin function we have noted in Cd39-
[lull endothelial cells. There appears to he a sustained defect in the activation 
of the FAK and downstream ERK]/2 pathway in Cd39-null endothelia] 
cells, while the FAK, PI-·J kinase, Akt pathway remains unaffected. 
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Figure 5.C).4 - f;raphit rt'presentatiotl of Aklphosphor~'tation in 
wild-t~'pe and Cd39-nulJ endothelial cells at 0, 15. 30 and 60 
minutes after plating ollto\'itronee1in. Bar l'harts t<-present 
d~nsitometry result.; (means ~ s.e.m) of phosphl)rylated A.kt 
dho'ided by total Akt. RepresentatiH blots. are s.hown b<-Iow graphs. 
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We have hypothesized that purinergic receptors may form complexes with 
and assist in the acti vation of cell-surface inlegrins. This has been shown to 
occur with P2Y2 and (XvI)" but may also occur with other pllrinergic 
receptors and intcgrin combinations. CD39 may modulate thiS interaction in 
several ways. Firstly, the absence of CD39 may result in P2-receptor 
desensitization because of excess nucleotide concentrations at the cell 
sllrt'ace. This may alter the interaction between pllrinergic receptor and 
integrin and result in integrin inactivation. \rVe have shown previously that 
Cd39-nulJ platelets fail to activate integrin n m,/3] in response to ADP because 
of desensitization of the platelet ADP receptor, P2y j •
18
-+ 
Second Iy, CD39 is targeted to caveolae on tbe cell surface and may associate 
directly with integrins and purinergic receptors in a signaling complex. 197,If)k 
Deletion of Cd39 may result in integrin inactivation because of absence of 
this protein in the signaling cornplex rather than by loss of nucleotide 
hydrolysis at the cell surface. 
In order to resolve this qu stion, we pre-treated the wild-type and Cd39-null 
endothelial cells with soluble Grade VII apyrase. Grade vn apyrase is a 
soluble enzyme, prepared from potato, which efficiently hydrolyzes ATP 
and ADP down to AMP. It thus acts as a soluble surrogate for CD39. Pre-
treatment of Cd39-null cells with apyrase would correct nucleotide-induced 
P2-receptor desensitization, but would not replace the deleted CD39 protein 
in the putative integrin-purinoceptor-ectonucleotidase signaUng complex. 
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Figure 5.9.5 shows the vitronectin-induced activation of FAK in wild-type 
and Cd.39-null endothelial cells after pre-treatment with apyrase for 6 hours. 
In kl:eping with our finding that apyrase pretreatment corrects Cd39-nul1 
endothelial cell adhesion to vitroncctin, treatment with soluble apyrase also 
corrects defective vitronectin--induced signaling to FAK and ERK1I2 in 
Cd39-nutl cdls. 
Plating wild-type endothelial cells onto vitronectin induces rapid and 
sustained phosphorylation of FAK from 15 minutes through 60 minutes. 
T'his FAK activation is unaffected by apynlse pre-treatment, an expected 
finding because wild-type endothelial cells express functional CD39 in 
culture. [84 In Cd3 9-nu II endothelial cells, pre-treatment wi th apyrase 
completely corrects the defect ill signaling throughFAK (15 minutes. wild-
type IO()(;)J VS. Cd39-nuU 78.6(lr). P=O.14. 30 minutes, wild-type 73.2% vs. 
Cd39-null 81.2%. P::::0.27. 60 minutes, wild-type 113.) vs. Cd39-null 
89.2%. P=O.29). 
Similarly in the ERKl/2 activation experiments, pre-treatment with apyrase 
completely corrected the defective vitronectin-indllced acti vation of ERKJ /2 
in Cd39-nuJI endothelial cells. As shown 111 flgure 5.9.6, there was no 
signiricant difference in the activation of ERKII2 at 30 minutes (wild-type 
.8 vs. Cd39-null 90.7%. P=O.34) and 60 minutes (wild-type 100% vs. 
CJ39-null 96%. P=O.07) after plating onto vitronectin. At 15 minutes, 
ERK 1/2 activation was actually higher in Cd39-null cells relative to the 
wi Ill-type (wild-type 41.1 % vs. Cd39-null 68%. P=O.O 1). However, this is 
probably just a consequence of rapid Llcti vation of MAPK occurring at this 
time in both wild-type and Cd39-11Ull cells, which renders the experiment 
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ex.quisitely sensitive to variations Hl timing. Therefore, we feel that the 
increased activation of MAPK at 15 minutes in CdJ9-null cells is not a result 
of enhanced integrin signaling in Cd39-nu 11 cells following apyrase pre-
treatment. 
In conclusion, we have shown that there is defective activation of FAK and 
ERK1I2 in CdJ9-null endothelial cells after ligation of integrin (x\'Pjf~s by 
vitronectin. In addition, we have shown that this defective integrin-mecliated 
signaling in Cd39-null cells is completely corrected by reconstitution of the 
ectonucleotidase function or CD39 by soluble apyrase. This implies that the 
defective "outside-in" integrin signaling in Cd39-null cells occurs because of 
P2-receplor desensitization, and not because of CD39's structural role in 
cell-surface signaling complex assembly. It also suggests that reconstitution 
or desensitized purine receptors is sufficient for normal u vI3jl·:'L, activity in 
Cd39-null endothelial cells. 
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Figures 5.9.5 ~tnd 59.6 - PhosphoQ'iation of FAK (Fig 5.9.4) and 
ERK 112 (Fig 5.9S) in wild-t~'pe and Cd39-null endothelial ceiL<. 
pretreated for 6 hours with soluble ap:yrase (5unit"/ml). Bar charts 
represent densitometr), results (means ~ s.em) of phosphorylated 
f'AK or ERK1I2 divided by total FAK or ERK1l2. resprtti'\'el~·. 
RepresenlatiH blot~ arc shown below graphs. 
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5.10 DIFFERENTIAL EXPRESSION OF ACTIV Al'ED 
"LIGAND-RECEPTIVE" U VJ33 BY INIM1JNO· 
CYTOCHENHSTRY 
5.10.1 INTRODLJC'fION 
269 
fn order to test our hypothesis that there is defective integrin activation in 
Cd39-null mouse lung endothelial cells, we analyzed the expression of 
activate integrin (X Vf:$3 relative to total ctvf3\ using the synthetic antibody 
WOW-l. 
WOW·-l is novel synthetic ligand specific for activated integrin ctvl):1' which 
was developed by a group at the Schripps Research Institute in California. It 
was determined that adenovirus enters eukaryotic cells by binding only to 
activated u VI3]. The adenovirus penton base that binds uVri3 was isolated and 
using a technique called patch engineering was grafted into a monovalent 
flab antibody PAC I that is specific for activated C.(mJ-)3. This created a new 
monovalent Fab antibody that was shown to be specific for activated U VI)3' 
and have no atlinity for U lTh [)3.
2SJ The antibody has been shown to have 
activity against transfected human (.(vf5\ and against Uvf)j expressed on 
hovine aortic endothelial cells. ~81,28'1 Although never tested on murine cells, 
we hypothesized that, since WOW -I was developed as a chimeric protein 
with specificity for the uvI):1-binding domain, we could show positive 
staining on murine endothelial cells. 
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A kind gift of WOW-l antibody from Sanford Shattil, then at the Scripps 
Institute, afforded us the opportunity of analyzing the activation status of 
(xvl3 J on wild-type and Cd39-null mouse lung cndolhelial cells directly, 
without havirw to use surrogate markers like cellular adllesion alld " ~, 
intracellular signaling. 
5.10.2 METHODS 
a) FACS analysis 
110 Wild-type and Cd39-null mouse lung endothelial cells were grown to 
70()b confluence in normal endothelial media, then detached by 
trypsinization and resuspended in FACS buffer at O.5x 105 cellsl 
experiment. 
.. 50~llj anti-cxv or WOW -1 anti body (1 !lg/mL) was added and incubated 
on ice for 15 minutes. 
110 After washing, 50f.{L FITe-conjugated nuorescent secondary antibody 
was added and incubated on ice for ]5 minutes. 
110 Expression of total a v integrin and activated (Xvf33 on wild-type and 
CdJ9-null endothelial cells was measured by Huorescence-activated 
cell sorter (FACS) analysis with excitation at 4R8nm (blue) and 
detection a1530nm (green). 
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b) Immunocytoc hemistry 
.. ImrnunoCluorescent staining of endothelial cells performed as 
described in 5.2.1 (b) using anti-C1 v (I :200) and WOW -I (I: 100) as 
primary antibodies. 
5.10.3 R l:f S [T I ~I~ S~' .1 .. .Jk. ' . ..J k 
We have demonstrated that Cd39-null endothelial cells have defective 
integrin u.vI31/i35 function on the basis of defecti ve vitronectin-induced 
cellular adhesion and intracellular signaling. However, the expression of the 
Cl.v-integrin subunit is equal on wild-type and Cd39-nul1 endotbelial cells and 
the non-specific integrin activator Mnel: can correct the defective a.dhesion 
of Cd39-l1ul1 endothelial cells. This suggests that (lvl); integrin is expressed 
by Cd39-null endothelial cells, but that the integrin is expressed in an 
inacti vc state. 
[n order to prove that (;(VPl is expressed but inactive on Cd39-null cells we 
analyzed wild-type and Cd 3 9-nu II cells by flow cytometry and 
imrnullocytochemistry using a synthetic antibody specific for active u.v~)' 
namely WO\V-I. 
In their initial publication or the development of WOW-l ,2B3 the authors 
demonstrated its specificity for activated nVr:~3 using flow cytometry analysis 
of CHO cells stably transfected with Ct. vf3l' or n rnJ)3. They showed that 
WOW -\ bound to ctVP1-' but not Ci. 11b15 \-Iransfected cells. Also, acti vatioll of 
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the integrins usmg phorhol I myristate 13-acetate (PMA) and M nC1 2, 
significantly increased the binding of WOW-l to the cx Vl3J-transfectcd ceJls. 
This demonstrated that WOW-l was not only specific for CLyl)3' but on ly 
hound to the integrin in its activated status. 
Unfortunately, when we analyzed wild-type and Cd39-null endothelial cells 
using anti-CLy intcgrin and WOW-l antihodics, we failed to get a positive 
shirt in tJuorescent intensity in either wild-type or Cd39-nul1 cells with either 
the anti-uv integrin or WO\V-J antibodies. In contrast, probing with an anti-
CD31 antihody resulted in a strong signal in hoth wild-type and Cd39-null 
cells (results not shown). 
There are a number of possible explanations for this finding. Firstly, 
trypsinization may have damaged the cells prior to flow cytometry analysis. 
Although it is possible that trypsin could have a greater effect on intcgrins 
expressed on the cell surface than it does on CD] I, the fact that robust 
integrin-activated signaling through FAK and MAPK occurs 15 minutes 
after trypsinization implies that the <Lvi}) integrin is not significantly 
damaged in this process. 
Alternatively, (lvl)j may be expressed in an inactive state in solution prior to 
now cytometry analysis. However, treatment with MnC12 failed to increase 
the binding of WOW-I in either the wild-type or Cd39-null cells (results not 
shown), In addition, we also failed to show a signal using a polyclonal 
antibody specific for the <Xv integrin subunit. The binding of this antibody is 
unaffected by integrin activation status. 
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The most likely explanation is that the expression levels of U v integrin on 
both wild-type and Cd39-llull mouse lung endothelial cells is too low for 
analysis by flow cytomctry. The initial study describing \VOW -I used cells, 
which had been transfectecl with intcgrin cx. vf33 prior to flow cytornctry. In 
fact, untransl'ected control ClIO cells had poor binding of WOW-l in this 
study.2H4 
\Ve know that (Xvi), is up-regulated in proliferating angiogenic endothelium 
in ViVO.2~5 The endothelial cells we used in this experiment may approximate 
this condition in that they are derived from proliferaling cells in culture, 
which have been exposed to 11 numher of endothelial growth factors. 
However, the expression of Clvf3; was still not elevated to a level, which we 
could detect by flow cytometry. 
Therefore, \ve decided to ilnalyze the expression of activated integri n (X v[33 
by immunocytochemistry. In a second publication by the group that 
developed the WOW-I antibody, it was demonstrated that, after plating of 
bovine aortic endothelial cells ontc) fibrinogen, activated u vl3} is recruited to 
larnmellipodia at the protrusive edges of endothelial cel1s.n4 Because they 
had achieved a usable WO\\1-J signal in a non-transfected cell line, we 
decided to test the WOW-l antibody on wild-type and Cd39-null endothelial 
cells plated on a glass slide. 
We first coated the glass slides with gelatin to increase the attachment of the 
endothelial cells prior to staining. We specifically chose gelatin, which is not 
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a ligand for f1 vfi 1, because the WO\V-J antibody is specific for activated, 
unbound CI'vi33 integrin. 
As expected from the !low cytomctry experiments the expression of GVri3 
was very low on both wild-type and Cd39-null endothehal ceJls. However, 
in this experimental model we were able to show a high fidelity signal using 
the anti-<xv integrin subunit antibody. 
17igure 5.10.1 shows the expression of the c:l.y-integrin subunit on wild-type 
and Cd39-null mouse lung endothelial cells. It can be seen that the a v·· 
integrin subunit is expressed on both wild-type and Cd39-null endothelial 
celis, and that there is no significant difference in the expression levels 
between each cell type. '1'his is consistent with our previous Western blot 
analyses or Cl.v-integrin expression, which showed no difference in the 
expression of oyintegrin on wild-type and Cd39-null endothelial cells. 
Unfortunately, we could not show similar results usmg the \VOW-J 
antibody. Repeated attempts at achieving a positive signal using this 
antibody failed in spite of MnC12-imiuced activation of surface integrins. 
Since we were able to demonstrate (xy-integrin expression by 
immunofluorescence using the anti-<xy-integrin subunit antibody, we 
concluded that the WOW-l antibody was either not specific for murine 
(Xvi)], or the batch of antibody we had been given was inactive. Since WOW-
I is not a commercially avai [able antibody, we could not confirm species 
specificity or purchase more antibody, We \-vere therefore unable to confirm 
the nature of etvl), activation on the surface of Cd39-null endothelial cells. 
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F'igure 5.10.1 . Irrununolluorestent staining (red) of a".integrin 
(upper panel) and WOW-l (lower panel) on wild-type (I('ft) and 
CdJ9-null (right) t'ndothdial tdls. l\llte qualitati~'eJy eqmtl ex,-
i"tegrin staining, but ~tb~nce of WOW-l stainin.g. N(-gaHve (:()ntrol 
wjth only S('oConda~' anti 00d)' (HuoN!Scein~onugltted rabbit anli-
rat IgG) shown below. Cell nuclej are stained biue (Hol'S(·ht). 
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CIIAPTER 6: I)ISCUSSION 
W c have shown that abnormal purmerglC signaling in the Cd3 9- null 
vasculature results in profound defects in both physiological and 
pathological angiogenesis. Deletion of the majority of vascular 
ectol1ucleotidase activity results in defective MatrigePM plug-induced 
angiogenesis,2Jci abnormal liver regeneration following hepatic resection and 
disordered cardiac remodeling following experimental myocardial 
infarction. In addition, decreased angiogenic responses in the Cd39-nuIJ 
mouse led to markedly decreased growth of implanted tumours and of 
tll mo ur metastases. 
Angiogenesis is characterized initially by vcsscl diJation, increased 
permeability and fibrin deposition. Maturation of newly formed blood 
vessels requires the formation of cndothelial tubcs surrounded by new 
basement membrane and the recruitment of pericytes and smooth muscle 
cells around the new endotheJium. 286 
Cd39-null mice exhibit normal initial phases of angiogenesis, including 
mother vessel formation, increased vascular permeability and fibrin 
deposi tion. However, there is a profound defect in the migration of 
endothelial and inflammatory cells into tumours in Cd39-null animals. There 
is also abnormal resolution of angiogenesis in Cd39-null mice characterized 
by poor recruitment of surrounding pericytes and smooth muscle celts to 
new blood vessels, As embryonic vascular development is normal in Cd39-
null mice,lx4 our data suggests that purinergic signaling has differential roles 
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If! physiological blood vessel developrnent as opposed to pathological 
. . 
angIogenesIs. 
Despite this defect in tumour angiogenesis, deletion of Cd39 is associated 
with the development of spontaneous hepatocellular carcinomas in aged 
mice (Sun Xiaofeng, unpublished observation). These carcinomas are 
characterized by the development of large sinusoidal blood vessels, rather 
than true angiogenic microvasculature. This implies that alternate 
mechanisms of tumour vascularization, perhaps co-opting of existing 
vasculature, compensated for the observed defects in endothelial cell 
migration and angiogenesis. 
Our initial in vitro analyses demonstrated that the defective angiogenesis in 
Cd39-null mice did not occur because of defects in endothelial cell 
proliferation, apoptosis or matrix metalloproteinase expression. Rather, we 
showed that the cellular migration defect in Cd39-null mice occurs because 
of abnormal vitronectin receptor (c:tvfLw,) function in Cd39-null endothelial 
cells. 
Although several members of the integrin family have been implicated, the 
largest body of data has linked the vitronectin receptor C:t V [) 1 with the 
promotion of neovascularization. Numerous o.VI)3 antagonists, including 
blocking antibodies directed at the extracellular domain of C:t\J'>J (LM609), 
inhibit angiogenesis in experimental animal models34 and are currently 
undergoing human clinical trials.;~2,) Matrix metalloproteinase-2 (MMP-2) 
also co-localizes with (:tvl)] and may direct proteolytic activity at the leading 
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edge of migrating endothelial cells"5. Inhibition of this interaction, without 
blocking either Cl. v13 J or MMP-2 function, inhibits angiogenesis in ViV011i92X7. 
Despite the efficacy of these Civl~l inhibitors, genetic deletion of (x v l3 J 
results in increased tumour angiogenesis. 129 It has been proposed that 
integrins might provide positive and/or negative signals to cells in the 
presence of appropriate extracellular ligands,Uo Absence of these 
interactions could result in loss of putative negative signal(s) and enhanced 
angiogenesis. 'These observations imply that Ci vf3, could be involved in the 
fine-tuning of angiogenesis responses ill vivo, 
We have shown that normal purinergic signaling is also required for Ci vf3 3 
function and for angiogenesis. Cellular signaling by G protein--coupled 
receptors (GPCRs), such as P2Y-receptors, involves not only the coupling of 
the receptors to G proteins, but also the formation of large protein complexes 
that assist in transmitting an extracellular signal to an intracellular 
response20H ,209. P2Y2 contains an integrin-binding, arginine-glycine-aspartic 
acid (RGD) domain in its first extracellular loop, suggesting interactions 
with intcgrin (Xvfll; mutation of the RGD sequence to RGE, decreased the 
co-localization of (1. ntegrins with P2Y2 ten-fold and greatly impaired 
UTP-induced phosphorylation of FAK.195 
Direct association bet\veen P2Y2 and cJ.v-,integrins appears to also be 
necessary for UTP-induced endothelial cell migration, implying an 
irnportant link between purinergic signaling, integrin function and pro-
angiogenic cellular behaviors204 . We hypothesize that deletion of Cd39 
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results tn differential P2-receptor desensitization, whjch subsequently 
modulates the activity of (XVf:S3' In keeping with this supposition, MnC12 and 
apyrase pretreatment of Cd39-null endothelial cells was able to normalize 
function of cxvfL" impJying that P2-reccptor desensitization and secondary 
integrin inactivation is responsible Cor these findings. 
We have recently published that the N-tenninus of CD39 interacts with the 
multi-adaptor scaffolding membrane phosphoprotein, RanBPM.:'57 RanBPM 
binds the HGF-receptor cMET and modulates a number of intracellular 
signaling cascades, in particular the Ras-ERK-SRE pathway.2iS~ In addition, 
l~anBPM interacts with LFA-l (lymphocyte function-associated antigen-I) 
and integrins and may affect integrin activation and signaling pathways 
ciircctly,28'J These results suggest that CD39 may regulate ceLlular sjgnaJ 
transduction pathways and integrin function by two separate mechanisms. 
Firstly, by modulating P2 receptor function following hydrolysjs of 
extracellular nuclcotides, and secondly, by interacting with other signaiing 
proteins, possibly using RanBPM as a bridge. 
An important future direction for study would be to determine which P2-
receptors are important for the proposed (XvI), activation/inactivation. This 
study is limited by the lack of truly speciJic P2-receptor agonists and 
antagonists. IBO Additionally, P2-receptor desensitization likely involves 
receptor phosphorylation or uncoupl ing of the receptor from its associated 
(I-protein. 'This suggests that simple RT-PCR analysis of P2-receptor 
expression in wild-type and C'd39-null endothelial cells would unlikely 
identify the involved P2-receptors. 
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The most rational approach would be to target those P2-receptors with 
known links to (tV~3' for example P2y2.
I
l)S P2Yz desensitization has been 
linked to phosphorylation sites on the C-terminus of the receplor. 290 An 
approach would be to use C-terminal truncation mutants of P2Y2 in systems 
involving Cd39, to determine whether mutation of P2Y2 reverses the (;(V~l 
inactivation noted in Cd39-null cells. Alternatively, P2Y], P2Y2 and P2Y. 
knock-out animals have already been developed, and these could be used to 
develop double knock-out animals witb Cd39-null mice to test this 
hypothesis further. 291-293 
Two Src homology-3-binding sites on P2Y:: have been shown to be 
responsible for UT'P-induced transactivation of vascular endothelial growth 
factor receptor (VEGFR)-2 by P2Y2.294 This implies that P2Y2 
desensitization may result in VEGF-signaling defects in Cd39-nul1 animals. 
Our data suggest that deletion of Cd39 is not associated with defects in 
VEGF signaling in vitro, but further work is required to examine this 
possibility in settings involving activation of P2Y2 by UTP. 
An additional hypothesis exists for the development of integrin dysfunction 
following Cd39 deletion. In addition to modulating P2-receptor signaling by 
nucleotide hydrolysis, CD39 also generates adenosine by hydrolyzing ATP 
and ADP to AMP, which is subsequently converted to adenosine by the 
action of ecto-5'-nucleotidase (CD73). Adenosine has also been shown to 
have important pro-angiogenic functions. For example, adenosine, acting 
VIa the A2A -receptor, promotes wound healing by stimulating 
angiogenesis. :Ill 
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It is certainly possible that deletion of Cd39 results in decreased production 
of adenosine and that it is the lack of this pro-angiogenic factor, rather than 
P2-receptor desensitization, which leads to defective angiogenesis in Cd39-
null mice. 
Further work is required to examine of this possibility. For example, we 
have recently studied the effect of the non-selective adenosine agonist 5'-N-
ethy lcarboxarnidoadenosine (NECA) on intracellular signal ing events 
following Ctvf):; ligation. Preliminary results suggest that NECA docs not 
correct defective FAK and ERKII2 activation in Cd39-null endotbelial cells 
(preli rninary data, not shown). This implies that P2-receptor desensitization, 
rather than lack of adenosine effects is responsible for the defective function 
of cXv!.)j. \Ve still need to study the effects of NECA on endothelial cell 
adhesion, as well as confirm our findings with other synthetic adenosine 
analogues. 
'fhe Cd73-null mouse would provide another avemle to study the role of 
adenosine in angiogenesis in vivo and in vitro. Deletion of ecto-S'-
nucleotidase (CD73) would result in decreased production of adenosine from 
purine monophosphates and potentially defective angiogenesis. It would also 
be interesting to examine whether Cd73-nul1 endothel ial cells have similar 
defecti ve o'yf3 , function in vitro, implying that oLir findings in Cd39-null 
celJs are secondary to decreased adenosine generation. 
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A final important avenue to study would be the role of anti-tumour immune 
mechanisms on tumour growth in wild-type and Cd39-null animals. Ohta et 
a1. have recently repc)fted that A 2A-receptor signaling inhibits anti-·tumour 
Jymphocytes and promotes tumour growth in vivo?)) They propose targeting 
thL~ hypoxia -+ adenosine -+ A 2A-receptor pathway in order to prevent the 
inhibit.ion of anti-tumour immune ceUs within the hypoxic tumour 
microenvironment2fJS This finding h"15 important implications for our work 
as Cd39-nulJ animals may have decreased inhibition of anti-tumour 
lymphocytes because of limited generation of adenosine. In this regard, we 
have evidence that CD39 forms an important part of the immunosuppressive 
apparatus of regulatory T cells (Treg), at least in part via the generation of 
adenosine (S. Deaglio, K. Dwyer, rnanuscript submitted). 
rr'he most exciting aspect of our work on CD39 anci angiogenesis is that we 
may be able to modulate purinergic signals therapeuticalJy in the future. 
Soluble derivatives of C039 have already been proposed as effccti ve <lnti-
thrombotic or anti-inflammatory therapies. 234 Our findi ngs raise the 
possibility of new anti-angiogenesis therapies based on modulating 
extracelluJar nucleotide-mediated signals. rrhese goals could be achieved by 
either blocking the action of C039 directly, or by targeting those nucleotide 
(P2) receptors that are important in activating integrins during angiogenesis. 
It is our hope that purinergic signaling systems may become an important 
target of anti-angiogenic cancer therapies. 
Our results also demonstrate a caveat to the use of soluble CD39 derivatives 
as anti-thrombotic and anti-inflammatory therapies. We have shown that 
single doses of apyrase increases the development of pulmonary metastases 
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in both wild type and Cd39-l1ullmicc. This suggests that ectonucleotidases 
might promote tumour cell seeding <lnd consequent survival in the 
pulmonary v'lsculature. The implic~ltion is that CD39-based therapies may 
pro/note turnour metastasis and will require careful monitoring with human 
Lise. 
In cone 1 us ion, we ha ve provided t~vidence for the importance of purinergic 
angiogenesis in disease and described novel links between purinergic 
signaling and integrin activation. These findings raise the possibility of new 
anti-angiogenesis therapies based on modulating extracellular nucleotide-
mediated signals. 
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CIIAP'rER 7: APPENDICES 
7.1 ABBREVIATIONS 
('.(-SMA 
I}-Hec; 
Akt 
AMP, ADP, ATP 
Ano-l 
b ' 
A'TCC 
BrdU 
CAM 
CFTR 
dNTP 
DAB 
DMEM 
DMSO 
DTT 
ECM 
EGF 
EHS 
ELISA 
E-NTPDase 
EC 
('i-smooth muscle actin 
r:~-humal1 chorionic gonadotrophin 
protein kinase B 
adenosine 5' -mono, di, triphosphate 
angiopoietin- J, -2 
American Type Culture Collection 
5-bromo-2-deoxyuridine 
chick chorioallantoic membrane 
cystic fibrosis transmembrane conductance 
regulator 
deoxyribonucleoside triphosphate 
3,3-diaminobenzidine tetrahydrochloride 
Dulbecco's Modified Eagle Medium 
dimethyl sulphoxide 
dithiothreitol 
extracellular matrix 
epidermal growth factor 
Engelbreth-Holm-Swarm 
enzyme-linked immunosorbent assay 
ecto-nuc1eoside triphosphate diphosphohydrolase 
endotheLial cell 
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EDTA 
ERBB2 
ERKI/2 
ES 
E-NPP 
FACS 
FAK 
FBS 
FDA 
FGF 
FJTC 
GDP 
GPr 
Grb2 
I-lSPG 
HGr·' 
HIF-Icl.. 
HUVEC 
rCAM-2 
IFN-ex 
ILF 
ILK 
rGF-l 
285 
ethylenediamineletraacetic acid 
v-erb-b2 erythroblastic leukaemia viral oncogene 
homologue 2 
extracellular signal-regulated kinase 1/2 
embryonic stem 
ectonucleotide pyrophosphatase/phosphodiesterase 
Fluorescence Activated Cell Sorting 
focal adhesion kinase 
fetal bovine serum 
Food and Drug Administration 
fibroblast growth factor 
l1uorescein isothlocyanate 
guanosine 5' -diphosphate 
gl ycosylphosphatidy linos i to I 
growth factor receptor-bound protein 2 
heparin-sulphate proteoglycan 
hepatocyte growth factor 
hypoxia-inducible transcription factor 1(1, 
human umbilical vein endothelial cells 
intracellular adhesion molecule 2 
in terferon -CI. 
irintecan, nUDrouracil and leucovorin 
intcgrin-linked kinase 
'-
insulin-like growth factor 
inositol 1,4,S-tripbosphate 
leukocyte common antigen (CD4S) 
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LLC 
MAPK 
MEK 
MMP 
MT-MMP 
M'TT 
NAD 
NEJM 
NF;'-KB 
NK 
NRP-\ 
NTPDase 
PAl-I 
PAK 
PBS 
PDGF-13 
peR 
PECAM-I 
PGI2 
prGF 
PLC 
PMA 
PMSF 
PI 3-kinase 
ReID 
Lewis lung carcinoma 
mitogen activated protein kinase 
mitogen activated protein kinase kinase 
matrix rnetalloproteinase 
mCITlbrane-type rnetalloproteinases 
[3-( 4,5-dimethy Ithiazol-2-y 1)-2,5-
di pheny ltetrazoli urn bromide] 
nicotinamiJe adenine dinucleotide 
New EngJand Journal of Medicine 
nuclear factor-KB 
natural killer 
neuropilin-J 
nucleoside triphosphate diphosphohydrolase 
plasminogen activator inhibitor-l 
p21-activated kinases 
phosphate·-buffered saline 
platelet-derived growth factor-13 
polymerase chain reaction 
platelet/endothelial cell adhesion molecule 1 
prostaglandin 12 (prostacyclin) 
placenta growth factor 
phospholipase C 
phorbol 12-myristate J 3-acetate 
phenylmethylsuJphonyJ nuoride 
phosphoinositide 3-0H kinase 
arginine-glycine-asparagine 
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RGE 
RfPA 
RNAse 
SDS 
SOS-PAGE 
SH2/SH3 
5MB 
SOS 
TAF 
TCA 
'I'd'!, 
TGF-I 
TGF-(x 
'!'OF-/.) 
TIMP 
TNF-C( 
t-PA 
TSP-l 
Tuncl 
LJMP, UDP, UTP 
U-PA 
u-PAR 
VEOF 
aro- inine- u ] \/cine- (J Iutamic acid 
b b J b 
radioimrnunoprecipitation assay 
ribonuclease A 
sodium dodecyl sulphate 
sodium dodecyl sulphate polyacrylamide gel 
electrophoresis 
Src homology 2/3 domain 
somatomedin 13 
son of sevenless 
tumour angiogenesis factor 
trichloroacetic acid 
terminal deoxynucleotidyl transferase 
transforming growth factor-l 
transt'ormin u IJrowth factor-a Ob 
transforming growth [actor-[3 
tissue inh ibitors of rnatrix metalloprotei nases 
tumour necrosis factor-a 
tissue-type plasminogen activator 
thrombospondin-I 
Terminal deoxynucleotidyl Transferase Biotin-
dUTP Nick End Labeling 
uridine 5' -mono, di, triphosphate 
urokinase··type plasminogen activator 
urokinase-type plasminogen activator receptor 
vascular endothelial growth factor 
287 
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VEGFR-l,-2 
v\vr;' 
VPF 
VE-cadherin 
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vascular endothelial growth factor receptor-l O::;lt-
I), -2 (Flk-liKDR) 
von Willebrand factor 
vascular permeability factor 
vascular endothelial-cadherin 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
7.2 IVIATERL\LS ANI) SlJPI1LIERS 
7.2.1 ANTIBODIES 
• a~smooth muscle actin 
- Sigma-Aldrich Corp. St. Louis, MO 
• Akt 
.. Cell Signaling Technology, Inc. Danvers, MA 
• CD16/CD32 (FqIH/H) 
- BO Biosciences Pharmingen. San Jose, CA 
• CD31 (PECAM-l) 
- BD Biosciences Phanningen. San Jose, CA 
.. CD61 (~.3 intcgrin subunit) 
- BO Biosciences Phanningen. San Jose, CA 
• CD 144 (VE cadherinl 
- 130 Biosciences Pharmingen. San Jose, CA 
• F4/80 (macrophage marker) 
- Serotec, Inc. Raleigh, NC 
• :FAK 
- CeIl Signaling Technology, Inc. Danvers, MA 
.. Fiuort~sccin-conjugatcd Goat anti-Rabbit IgG 
- Vector Laboratories. Burlingame, CA 
• Fluorescein-conugatcd Rabbit Anti-Rat IgG 
- Vector Laboratories. Burlingame, CA 
• Hepanm Sulphate Proteoglycan 
- CHEN{[CON International, Inc. Temecula, CA 
289 
Cat: A5228 
Cat: 9272 
Cat: 553142 
Cat: 553371 
Cat: 55054J 
Cat: 550548 
Cat: MCA497GA 
Cat: 328 
CatFI -1 000 
Cat: FTAOOO 
Cat: MAS 1948 
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• ICAl\1 ~2 antibody 
~ 130 Biosciences Pharmingen. San Jose, CA 
• Integrin a, chain 
- BD Biosciences Pharmingen. San Jose, CA 
• p44/42 MAP Kinase 
~ Cell Signaling Technology, Inc. Danvers, MA 
• Phospho~Akt (Ser473) 
- Cell Signaling Technology, Inc. Danvcrs,MA 
• Phospho-FAK (Tyr92S) 
- Cell Signaling Technology, Inc. Danvers, MA 
• Phospho-p44/42 MAP Kinase (Thr202/1'yr204) 
- Cell Signaling Technology, Inc. Danvers, MA 
• Pig anti-Rabbit F(ab')z 
Cat: 550544 
Cat: 550024 
Cat: 9102 
Cat: 4058 
Cat: 32H4 
Cat: 910 t 
- Dako North America, [nco Carpinteria, CA Cat: E043 1 
• Platelet derived growth factor (PDGFR-~) receptor 
- Santa Cruz Biotechnology, Inc. Santa Cruz, CA Cat: sc-339 
• Rabbit anti·Mouse F(ab')2 
- Dako North America, Inc. Carpinteria, CA 
• Rabbit Anti-Rat IgG 
Cat: E0413 
290 
- Vector Laboratories. Burlingame, CA Cat; 13A-4000 
• Vascular endothelial growth factor receptor-2 (VEGFR-2) 
- Kind gift from R. Brekken and P. Thorpe 
- University of Texas Southwestern Medical Center, Dallas 
• vonWilIebrand Factor 
- B D Biosciences Pharmingen. San Jose, CA Cat: 555849 
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7.2.2 REAGENTS 
.. Adenosine 
- Sigma-Aldrich Corp. St. Louis, MO 
.. Adenosine 5'-triphosphate (ATP) 
291 
Cat: A4036 
- Sigma-Aldrich Corp. S1. Louis, MO Cat: A6559 
.. ApopTag® Peroxidase In Situ Apoptosis Detection Kit 
- CHEMICON International, Inc. 'Iernecula, CA Cat: S7l 00 
.. Apyrase from potato (grad(~ VII) 
- Sigma-Aldrich Corp. S1. Louis, MO 
.. BenchMark™ Pre-stained Protein Ladder 
- [nvitrogcn Corp. Carlsbad, California 
.. Bovine Serum Albumin 
- Sigma-Aldrich Corp. St. Louis, MO 
.. 5-Bromo-2-deoxyuridine (UrdU) 
- Sigma-Aldrich Corp. St.Louis, MO 
.. BrdU Label ing and Detection Kit In 
- Roche Diagnostics Coq). Indianapolis, IN 
.. Collagenase, Type ] 
- Worthington Biochemical Corp. Lakewood, NJ 
.. Coomassie Blue 
- Bio-Rad Laboratories, Inc. Hercules, CA 
.. Creatinine Assay Kit 
- Sigma diagnostics, Inc. SL Louis, MO 
Cat: A6535 
Cat l074R-O 1 0 
Cat: A6003 
Cat: 858811 
Cat: 1444 611 
Cat: LS004] 94 
Cat: 161-0400 
Cat: 555A 
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.. Crystal 
- Sigma-Aldrich 
.. DC Protein Assay 
Laboratories, Inc. 
.. Dithiothreitol (DTT) 
s,MO 
S Corp. St. Louis, MO 
.. kit 
a,CA 
292 
J12 
]5 
Cat: 69504 
.. Dulbecco's Modified •. :''''.1;;1'' l\tledium (DMEJ\;I) (low glucose, plus 
GLUTAMAXTM) 
- Gibeo (Invitrogen 
.. Dynabeads (sheep 
- DynaI (lnvitrogen Corp) 
.. Endothelial J\1itogen 
Biomedical Technologies, Stoughton, MA 
l0567-014 
11 
<II F-12 Nutrient ~1ixture (Ham) (plus GLlJTAIVIAX™) 
Carlsbad, CA Cat: 3 
Cat: 16000-044 
.. Fibroblast 
- S MO 
.. Fihronection rat plasma 
- Sigma-Aldrich Corp. MO 
.. Gelatin (type B) 
.. S Corp. S1. Louis, MO 
.. Glycine 
S S1. MO Cut: 8898 
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• Goat serum 
- Sigma-Aldrich Corp. St. Louis, MO 
• Ht.~parin sodium salt 
- Sigma-Aldrich Corp. St. Louis, MO 
.. Hepatocyte Growth Factor (HGF) 
Cat: G9023 
Cat: H4784 
- Sigma-Aldrich Corp. St. Louis, MO Cat: H 1404 
• Hmnan Chorionic Gonadotropin (BCG) ELISA Kit 
- Al pha Diagnostics IntI. Inc. San Antonio, TX Cal: 0400 
• Insulin (Human lisproinsulin - humalog) 
- Eli Lilly and Co. Indianapolis, IN 
.. Insulin-like Growth J,'actor-l ClGF-1) 
- Sigma-Aldrich Corp. St. Louis, MO 
"L-GJutamine 
Cat: 13769 
293 
- Gibco (Invitrogen Corp) Carlsbad, CA 
• Laemmli (SDS) reducing buffer 
Cat: 21051-024 
- Boston BioProducts, Inc. Worcester, MA 
.. Liquid scintHlation mixture 
- Sigma-Aldrich Corp. St. Louis, MO 
" Manganese chloride CMnC1 2) 
- Sigma-Aldrich Corp. St. I,ouis, MO 
" 1\1atrigeFM (Growth Factor Reduced) 
- BD Biosciences. San Jose, CA 
.. (3-l\lercaptoethanol 
- Sigma-Aldrich Corp. S1. Louis, MO 
.. 2-methyl-2-butanol 
- Sigma-Aldrich Corp. S1. Louis, MO 
.. l\louse serum 
Cat: BP-llOR 
Cat: 327123 
Cat: M8054 
Cat: 356231 
Cat: M7154 
Cat: 240486 
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St. .MO 
0& Nonimmune J\Ilouse 
- Sigma-Aldrich Corp. St. Louis, MO 
0& Nonimmune Rabbit IgG 
Sigma-Aldrich Corp. St Louis,MO 
• ..... ~u~ Rat JgG 
Corp. St. Louis, MO 
(D3M, NEOP2, HJlLJ"-'U 
294 
M5905 
no: 
Cat: 14131 
• PenicH lin·8 treptomycin Penicillin, 5000lJ,g 
Streptomycin) 
- Gibeo (Invitrogen 
• Percoll (density 1.13mg/ml) 
- Amersham Bioseiences. Piscataway, NJ 
• Phorhol 12-myristate 13·acetate (P1VIA) 
Louis, MO Pl 
• 
• 
Cat: 70011-044 
(no calcium or magnesium) 
0& Porcine serum 
- Sigma-Aldrich Corp. LOll MO 
0& Precast polyacrylamide gels (4· 
Bio-Rad Laboratories, Inc. Hercules, CA 
• Proliferating Cell Nuclear Antigen 
• 
(Invitrogen Corp) Carlsbad, 
A-Sepharose® 
14200-075 
P9783 
16 J 11 
Kit 
I I 
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o. Sigma-Aldrich Corp. S1. Louis, MO 
.. Protease Inhibitor Cocktail Tablets 
- Roche Diagnostics Corp. Indianapolis, IN 
.. PVUF membrane 
295 
Cat: P3391 
Cat: 1836]53 
- Bio-Rad Laboratories, Inc. Hercules, CA 
.. Rabbit serum 
Cat: 162-0 J 77 
- Sigma-Aldrich Corp. St. Louis, MO 
.. Restore Western mot Stripping nuff{~r 
- Pierce Biotecbnology, Inc. Rockford, JL. 
.. Saponin 
- Sigma-Aldrich Corp. S1. Louis, MO 
.. Sodium dodecy1 sUlphate (SDS) 
- Sigma-Aldrich Corp. S1. Louis, MO 
.. Sphingosine-I-phosphate 
- BIOMOL Jnt. L.P. Plymouth Meeting, PA 
.. SuperSignal (Feluto) Chemiluminescent Substrate 
Cat: R9J33 
Cat: 21059 
Cat: 47036 
Cat: L3771 
Cat: SLI40 
Pierce Biotechnology, Inc. Rockford, lL. Cat: 34095 
.. SuperSignal (Pico) ChemHuminescent Substrate 
- Pierce Biotechnology, Inc. Rockford, IL. Cat: 34080 
.. TACS XL-Basic (In Situ Apoptosis Detection Kit) 
- R&D Systems, Inc. Minneapniis,MN Cat: TA 100 
.. Taq UNA Polymerase, Hot-Start Version Kit 
- Takara Bio Inc. Shiga, Japan 
.. Texas Red Avidin 0 
- Vector Laboratories. Burlingame, CA 
.. rmethyl.]Hj Thymidine (47 Ci/mmol) 
- Amcrsham Biosciences. Piscataway, N.I 
Cat: R007 A 
Cat: A-2006 
Cat: TRK637 
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.. 2~2,2-Tribromoethanol 
S Corp. 
acid 
100 
Sigma-Aldrich 
.. Trizma® 
Sigmu~Aldrich 
s, 
. MO 
Louis, MO 
MO 
.. Trypsin-EDT A solution 
Corp. 
inhibitor from nlf"YU> rflax (soybean) 
St. Louis, MO 
.. TWEEN® 
Sigma-Aldrich s,MO 
• Uridine 5' -triphosphate (UTP) 
Corp. St. 
... '7............. Endothelial Growth (VEGF') 
- S Corp. St. 
from plasma 
Sigma-Aldri ch MO 
TH787 
TI 
Cat: T6414 
Cat: 12 
V0132 
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